IB 
Union Calendar No. 348 
112TH CONGRESS 
2D SESSION 
H. R. 5651 
[Report No. 112–495] 
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend 
the user-fee programs for prescription drugs and for medical devices, 
to establish user-fee programs for generic drugs and biosimilars, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 9, 2012 
Mr. UPTON (for himself, Mr. WAXMAN, Mr. PITTS, Mr. PALLONE, Mr. BAR-
TON of Texas, and Mr. DINGELL) introduced the following bill; which was 
referred to the Committee on Energy and Commerce 
MAY 25, 2012 
Committed to the Committee of the Whole House on the State of the Union 
and ordered to be printed 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
revise and extend the user-fee programs for prescription 
drugs and for medical devices, to establish user-fee pro-
grams for generic drugs and biosimilars, and for other 
purposes. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Food and Drug Ad-
ministration Reform Act of 2012’’. 
SEC. 2. TABLE OF CONTENTS. 
The table of contents of this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents. 
Sec. 3. References in Act. 
TITLE I—FEES RELATING TO DRUGS 
Sec. 101. Short title; finding. 
Sec. 102. Definitions. 
Sec. 103. Authority to assess and use drug fees. 
Sec. 104. Reauthorization; reporting requirements. 
Sec. 105. Sunset dates. 
Sec. 106. Effective date. 
Sec. 107. Savings clause. 
TITLE II—MEDICAL DEVICE USER FEE AMENDMENTS OF 2012 
Sec. 201. Short title; findings. 
Sec. 202. Definitions. 
Sec. 203. Authority to assess and use device fees. 
Sec. 204. Reauthorization; reporting requirements. 
Sec. 205. Savings clause. 
Sec. 206. Effective date. 
Sec. 207. Sunset clause. 
Sec. 208. Streamlined hiring authority to support activities related to the proc-
ess for the review of device applications. 
TITLE III—FEES RELATING TO GENERIC DRUGS 
Sec. 301. Short title. 
Sec. 302. Authority to assess and use human generic drug fees. 
Sec. 303. Reauthorization; reporting requirements. 
Sec. 304. Sunset dates. 
Sec. 305. Effective date. 
Sec. 306. Amendment with respect to misbranding. 
Sec. 307. Streamlined hiring authority to support activities related to human 
generic drugs. 
TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL 
PRODUCTS 
Sec. 401. Short title; finding. 
Sec. 402. Fees relating to biosimilar biological products. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6211
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Sec. 403. Reauthorization; reporting requirements. 
Sec. 404. Sunset dates. 
Sec. 405. Effective date. 
Sec. 406. Savings clause. 
Sec. 407. Conforming amendment. 
TITLE V—REAUTHORIZATION OF BEST PHARMACEUTICALS FOR 
CHILDREN ACT AND PEDIATRIC RESEARCH EQUITY ACT 
Sec. 501. Permanent extension of Best Pharmaceuticals for Children Act and 
Pediatric Research Equity Act. 
Sec. 502. Food and Drug Administration Report. 
Sec. 503. Internal Committee for Review of Pediatric Plans, Assessments, De-
ferrals, Deferral Extensions, and Waivers. 
Sec. 504. Staff of Office of Pediatric Therapeutics. 
Sec. 505. Continuation of operation of Pediatric Advisory Committee. 
Sec. 506. Pediatric Subcommittee of the Oncologic Drugs Advisory Committee. 
TITLE VI—FOOD AND DRUG ADMINISTRATION ADMINISTRATIVE 
REFORMS 
Sec. 601. Public participation in issuance of FDA guidance documents. 
Sec. 602. Conflicts of interest. 
Sec. 603. Electronic submission of applications. 
Sec. 604. Notification of FDA intent to regulate laboratory-developed tests. 
TITLE VII—MEDICAL DEVICE REGULATORY IMPROVEMENTS 
Subtitle A—Premarket Predictability 
Sec. 701. Investigational device exemptions. 
Sec. 702. Clarification of least burdensome standard. 
Sec. 703. Agency documentation and review of significant decisions. 
Sec. 704. Transparency in clearance process. 
Sec. 705. Device Modifications Requiring Premarket Notification Prior to Mar-
keting. 
Subtitle B—Patients Come First 
Sec. 711. Establishment of schedule and promulgation of regulation. 
Sec. 712. Program to improve the device recall system. 
Subtitle C—Novel Device Regulatory Relief 
Sec. 721. Modification of de novo application process. 
Subtitle D—Keeping America Competitive Through Harmonization 
Sec. 731. Harmonization of device premarket review, inspection, and labeling 
symbols; report. 
Sec. 732. Participation in international fora. 
Subtitle E—FDA Renewing Efficiency From Outside Reviewer Management 
Sec. 741. Reauthorization of Third Party Review. 
Sec. 742. Reauthorization of third party inspection. 
Subtitle F—Humanitarian Device Reform 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6211
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Sec. 751. Expanded access to humanitarian use devices. 
Subtitle G—Records and Reports on Devices 
Sec. 761. Unique device identification system regulations. 
Sec. 762. Effective device sentinel program. 
Subtitle H—Miscellaneous 
Sec. 771. Custom devices. 
Sec. 772. Pediatric device reauthorization. 
Sec. 773. Report on regulation of health information technology. 
TITLE VIII—DRUG REGULATORY IMPROVEMENTS 
Subtitle A—Drug Supply Chain 
Sec. 801. Registration of producers of drugs. 
Sec. 802. Inspection of drugs. 
Sec. 803. Drug supply quality and safety. 
Sec. 804. Prohibition against delaying, denying, limiting, or refusing inspection. 
Sec. 805. Destruction of adulterated, misbranded, or counterfeit drugs offered 
for import. 
Sec. 806. Administrative detention. 
Sec. 807. Enhanced criminal penalty for counterfeit drugs. 
Sec. 808. Unique facility identification number. 
Sec. 809. Documentation for admissibility of imports. 
Sec. 810. Registration of commercial importers. 
Sec. 811. Notification. 
Sec. 812. Exchange of information. 
Sec. 813. Extraterritorial jurisdiction. 
Sec. 814. Protection against intentional adulteration. 
Sec. 815. Records for inspection. 
Subtitle B—Medical Gas Safety 
Sec. 821. Regulation of medical gases. 
Sec. 822. Changes to regulations. 
Sec. 823. Rules of construction. 
Subtitle C—Generating Antibiotic Incentives Now 
Sec. 831. Extension of exclusivity period for drugs. 
Sec. 832. Study on incentives for qualified infectious disease biological prod-
ucts. 
Sec. 833. Clinical trials. 
Sec. 834. Reassessment of qualified infectious disease product incentives in 5 
years. 
Sec. 835. Guidance on pathogen-focused antibacterial drug development. 
Subtitle D—Accelerated Approval 
Sec. 841. Expedited approval of drugs for serious or life-threatening diseases 
or conditions. 
Sec. 842. Guidance; amended regulations. 
Sec. 843. Independent review. 
Subtitle E—Critical Path Reauthorization 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6211
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Sec. 851. Reauthorization of the critical path public-private partnerships. 
Subtitle F—Miscellaneous 
Sec. 861. Reauthorization of provision relating to exclusivity of certain drugs 
containing single enantiomers. 
Sec. 862. Extension of period for first applicant to obtain tentative approval 
without forfeiting 180-day exclusivity period. 
Sec. 863. Final agency action relating to petitions and civil actions. 
Sec. 864. Deadline for determination on certain petitions. 
Sec. 865. Rare pediatric disease priority review voucher incentive program. 
Sec. 866. Combating prescription drug abuse. 
Sec. 867. Assessment and modification of REMS. 
Sec. 868. Consultation with external experts on rare diseases, targeted thera-
pies, and genetic targeting of treatments. 
Sec. 869. Breakthrough therapies. 
Sec. 870. Grants and Contracts for the Development of Orphan Drugs. 
TITLE IX—DRUG SHORTAGES 
Sec. 901. Discontinuance and interruptions of manufacturing of certain drugs. 
Sec. 902. Drug shortage list. 
Sec. 903. Quotas applicable to drugs in shortage. 
Sec. 904. Expedited review of major manufacturing changes for potential and 
verified shortages of drugs that are life-supporting, life-sus-
taining, or intended for use in the prevention of a debilitating 
disease or condition. 
Sec. 905. Study on drug shortages. 
Sec. 906. Annual report on drug shortages. 
Sec. 907. Attorney General report on drug shortages. 
Sec. 908. Hospital repackaging of drugs in shortage. 
SEC. 3. REFERENCES IN ACT. 
Except as otherwise specified, amendments made by 
this Act to a section or other provision of law are amend-
ments to such section or other provision of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). 
TITLE I—FEES RELATING TO 
DRUGS 
SEC. 101. SHORT TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Prescription Drug User Fee Amendments of 2012’’. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(b) FINDING.—The Congress finds that the fees au-
thorized by the amendments made in this title will be dedi-
cated toward expediting the drug development process and 
the process for the review of human drug applications, in-
cluding postmarket drug safety activities, as set forth in 
the goals identified for purposes of part 2 of subchapter 
C of chapter VII of the Federal Food, Drug, and Cosmetic 
Act, in the letters from the Secretary of Health and 
Human Services to the Chairman of the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
the Chairman of the Committee on Energy and Commerce 
of the House of Representatives, as set forth in the Con-
gressional Record. 
SEC. 102. DEFINITIONS. 
Section 735(7) (21 U.S.C. 379g) is amended by strik-
ing ‘‘expenses incurred in connection with’’ and inserting 
‘‘expenses in connection with’’. 
SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES. 
Section 736 (21 U.S.C. 379h) is amended— 
(1) in subsection (a)— 
(A) in the matter preceding paragraph (1), 
by striking ‘‘fiscal year 2008’’ and inserting 
‘‘fiscal year 2013’’; 
(B) in paragraph (1)(A)— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(i) in clause (i), by striking ‘‘(c)(5)’’ 
inserting ‘‘(c)(4)’’; and 
(ii) in clause (ii), by striking ‘‘(c)(5)’’ 
inserting ‘‘(c)(4)’’; 
(C) in the matter following clause (ii) in 
paragraph (2)(A)— 
(i) by striking ‘‘(c)(5)’’ inserting 
‘‘(c)(4)’’; and 
(ii) by striking ‘‘payable on or before 
October 1 of each year’’ and inserting 
‘‘due on the later of the first business day 
on or after October 1 of such fiscal year or 
the first business day after the enactment 
of an appropriations Act providing for the 
collection and obligation of fees for such 
fiscal year under this section’’; 
(D) in paragraph (3)— 
(i) in subparagraph (A)— 
(I) 
by 
striking 
‘‘subsection 
(c)(5)’’ 
and 
inserting 
‘‘subsection 
(c)(4)’’; and 
(II) by striking ‘‘payable on or 
before October 1 of each year.’’ and 
inserting ‘‘due on the later of the first 
business day on or after October 1 of 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
each such fiscal year or the first busi-
ness day after the enactment of an 
appropriations Act providing for the 
collection and obligation of fees for 
each such fiscal year under this sec-
tion.’’; and 
(ii) by amending subparagraph (B) to 
read as follows: 
‘‘(B) EXCEPTION.—A prescription drug 
product shall not be assessed a fee under sub-
paragraph (A) if such product is— 
‘‘(i) identified on the list compiled 
under section 505(j)(7)(A) with a potency 
described in terms of per 100 mL; 
‘‘(ii) the same product as another 
product that— 
‘‘(I) was approved under an ap-
plication filed under section 505(b) or 
505(j); and 
‘‘(II) is not in the list of discon-
tinued products compiled under sec-
tion 505(j)(7)(A); 
‘‘(iii) the same product as another 
product that was approved under an abbre-
viated application filed under section 507 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(as in effect on the day before the date of 
enactment of the Food and Drug Adminis-
tration Modernization Act of 1997); or 
‘‘(iv) the same product as another 
product that was approved under an abbre-
viated new drug application pursuant to 
regulations in effect prior to the implemen-
tation of the Drug Price Competition and 
Patent Term Restoration Act of 1984.’’; 
(2) in subsection (b)— 
(A) in paragraph (1)— 
(i) in the language preceding subpara-
graph (A), by striking ‘‘fiscal years 2008 
through 2012’’ and inserting ‘‘fiscal years 
2013 through 2017’’; and 
(ii) in subparagraph (A), by striking 
‘‘$392,783,000; 
and’’ 
and 
inserting 
‘‘$693,099,000;’’; and 
(iii) by striking subparagraph (B) and 
inserting the following: 
‘‘(B) the dollar amount equal to the infla-
tion adjustment for fiscal year 2013 (as deter-
mined under paragraph (3)(A)); and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(i) $652,709,000 plus the amount of 
the inflation adjustment calculated under 
subparagraph (A); multiplied by 
‘‘(ii) the amount (if any) by which a 
percentage workload adjustment for fiscal 
year 2013, as determined using the meth-
odology described in subsection (c)(2)(A), 
would exceed the percentage workload ad-
justment (as so determined) for fiscal year 
2012, if both such adjustment percentages 
were calculated using the 5-year base pe-
riod consisting of fiscal years 2003 
through 2007. 
‘‘(C) 
LIMITATION.—Under 
no 
cir-
cumstances shall the adjustment under sub-
paragraph (B) result in fee revenues for fiscal 
year 2013 that are less than the sum of the 
amount under paragraph (1)(A) and the 
amount under paragraph (1)(B).’’; 
(3) by striking subsection (c) and inserting the 
following: 
‘‘(c) ADJUSTMENTS.— 
‘‘(1) INFLATION ADJUSTMENT.—For fiscal year 
2014 and subsequent fiscal years, the revenues es-
tablished in subsection (b) shall be adjusted by the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Secretary by notice, published in the Federal Reg-
ister, for a fiscal year by the amount equal to the 
sum of— 
‘‘(A) one; 
‘‘(B) the average annual percent change in 
the cost, per full-time equivalent position of the 
Food and Drug Administration, of all personnel 
compensation and benefits paid with respect to 
such positions for the first 3 years of the pre-
ceding 4 fiscal years, multiplied by the propor-
tion of personnel compensation and benefits 
costs to total costs of the process for the review 
of human drug applications (as defined in sec-
tion 735(6)) for the first 3 years of the pre-
ceding 4 fiscal years, and 
‘‘(C) the average annual percent change 
that occurred in the Consumer Price Index for 
urban consumers (Washington-Baltimore, DC– 
MD–VA–WV; Not Seasonally Adjusted; All 
items; Annual Index) for the first 3 years of the 
preceding 4 years of available data multiplied 
by the proportion of all costs other than per-
sonnel compensation and benefits costs to total 
costs of the process for the review of human 
drug applications (as defined in section 735(6)) 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
for the first 3 years of the preceding 4 fiscal 
years. 
The adjustment made each fiscal year under this 
paragraph shall be added on a compounded basis to 
the sum of all adjustments made each fiscal year 
after fiscal year 2013 under this paragraph. 
‘‘(2) WORKLOAD
ADJUSTMENT.—For fiscal 
year 2014 and subsequent fiscal years, after the fee 
revenues established in subsection (b) are adjusted 
for a fiscal year for inflation in accordance with 
paragraph (1), the fee revenues shall be adjusted 
further for such fiscal year to reflect changes in the 
workload of the Secretary for the process for the re-
view of human drug applications. With respect to 
such adjustment: 
‘‘(A) The adjustment shall be determined 
by the Secretary based on a weighted average 
of the change in the total number of human 
drug applications (adjusted for changes in re-
view activities, as described in the notice that 
the Secretary is required to publish in the Fed-
eral Register under this subparagraph), efficacy 
supplements, and manufacturing supplements 
submitted to the Secretary, and the change in 
the total number of active commercial investiga-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
tional new drug applications (adjusted for 
changes in review activities, as so described) 
during the most recent 12-month period for 
which data on such submissions is available. 
The Secretary shall publish in the Federal Reg-
ister the fee revenues and fees resulting from 
the adjustment and the supporting methodolo-
gies. 
‘‘(B) Under no circumstances shall the ad-
justment result in fee revenues for a fiscal year 
that are less than the sum of the amount under 
subsection (b)(1)(A) and the amount under 
subsection (b)(1)(B), as adjusted for inflation 
under paragraph (1). 
‘‘(C) The Secretary shall contract with an 
independent accounting or consulting firm to 
periodically review the adequacy of the adjust-
ment and publish the results of those reviews. 
The first review shall be conducted and pub-
lished by the end of fiscal year 2013 (to exam-
ine the performance of the adjustment since fis-
cal year 2009), and the second review shall be 
conducted and published by the end of fiscal 
year 2015 (to examine the continued perform-
ance of the adjustment). The reports shall 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
evaluate whether the adjustment reasonably 
represents actual changes in workload volume 
and complexity and present options to dis-
continue, retain, or modify any elements of the 
adjustment. The reports shall be published for 
public comment. After review of the reports and 
receipt of public comments, the Secretary shall, 
if warranted, adopt appropriate changes to the 
methodology. If the Secretary adopts changes to 
the methodology based on the first report, the 
changes shall be effective for the first fiscal 
year for which fees are set after the Secretary 
adopts such changes and each subsequent fiscal 
year. 
‘‘(3) FINAL
YEAR
ADJUSTMENT.—For fiscal 
year 2017, the Secretary may, in addition to adjust-
ments under this paragraph and paragraphs (1) and 
(2), further increase the fee revenues and fees estab-
lished in subsection (b) if such an adjustment is nec-
essary to provide for not more than 3 months of op-
erating reserves of carryover user fees for the proc-
ess for the review of human drug applications for 
the first 3 months of fiscal year 2018. If such an 
adjustment is necessary, the rationale for the 
amount of the increase shall be contained in the an-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
nual notice establishing fee revenues and fees for fis-
cal year 2017. If the Secretary has carryover bal-
ances for such process in excess of 3 months of such 
operating reserves, the adjustment under this sub-
paragraph shall not be made. 
‘‘(4) ANNUAL
FEE
SETTING.—The Secretary 
shall, not later than 60 days before the start of each 
fiscal year that begins after September 30, 2012, es-
tablish, for the next fiscal year, application, product, 
and establishment fees under subsection (a), based 
on the revenue amounts established under subsection 
(b) and the adjustments provided under this sub-
section. 
‘‘(5) LIMIT.—The total amount of fees charged, 
as adjusted under this subsection, for a fiscal year 
may not exceed the total costs for such fiscal year 
for the resources allocated for the process for the re-
view of human drug applications.’’; and 
(4) in subsection (g)— 
(A) in paragraph (1), by striking ‘‘Fees 
authorized’’ and inserting ‘‘Subject to para-
graph (2)(C), fees authorized’’; 
(B) in paragraph (2)— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(i) in subparagraph (A)(i), by striking 
‘‘shall be retained’’ and inserting ‘‘shall be 
collected and available’’; 
(ii) in subparagraph (A)(ii), by strik-
ing ‘‘shall only be collected and available’’ 
and inserting ‘‘shall be available’’; and 
(iii) by adding at the end the fol-
lowing new subparagraph: 
‘‘(C) PROVISION FOR EARLY PAYMENTS.— 
Payment of fees authorized under this section 
for a fiscal year, prior to the due date for such 
fees, may be accepted by the Secretary in ac-
cordance with authority provided in advance in 
a prior year appropriations Act.’’; 
(C) in paragraph (3), by striking ‘‘fiscal 
years 2008 through 2012’’ and inserting ‘‘fiscal 
years 2013 through 2017’’; and 
(D) in paragraph (4)— 
(i) by striking ‘‘fiscal years 2008 
through 2010’’ and inserting ‘‘fiscal years 
2013 through 2015’’; 
(ii) by striking ‘‘fiscal year 2011’’ and 
inserting ‘‘fiscal year 2016’’; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(iii) by striking ‘‘fiscal years 2008 
though 2011’’ and inserting ‘‘fiscal years 
2013 through 2016’’; and 
(iv) by striking ‘‘fiscal year 2012’’ 
and inserting ‘‘fiscal year 2017’’. 
SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS. 
Section 736B (21 U.S.C. 379h–2) is amended— 
(1) by amending subsection (a) to read as fol-
lows: 
‘‘(a) PERFORMANCE REPORT.— 
‘‘(1) IN GENERAL.—Beginning with fiscal year 
2013, not later than 120 days after the end of each 
fiscal year for which fees are collected under this 
part, the Secretary shall prepare and submit to the 
Committee on Energy and Commerce of the House 
of Representatives and the Committee on Health, 
Education, Labor, and Pensions of the Senate a re-
port concerning— 
‘‘(A) the progress of the Food and Drug 
Administration in achieving the goals identified 
in the letters described in section 101(b) of the 
Prescription Drug User Fee Amendments of 
2012 during such fiscal year and the future 
plans of the Food and Drug Administration for 
meeting the goals, including the status of the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
independent assessment described in such let-
ters; and 
‘‘(B) the progress of the Center for Drug 
Evaluation and Research and the Center for 
Biologics Evaluation and Research in achieving 
the goals, and future plans for meeting the 
goals, including, for each review division— 
‘‘(i) the number of original standard 
new drug applications and biologics license 
applications filed per fiscal year for each 
review division; 
‘‘(ii) the number of original priority 
new drug applications and biologics license 
applications filed per fiscal year for each 
review division; 
‘‘(iii) the number of standard efficacy 
supplements filed per fiscal year for each 
review division; 
‘‘(iv) the number of priority efficacy 
supplements filed per fiscal year for each 
review division; 
‘‘(v) the number of applications filed 
for review under accelerated approval per 
fiscal year for each review division; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(vi) the number of applications filed 
for review as fast track products per fiscal 
year for each review division; and 
‘‘(vii) the number of applications filed 
for orphan-designated products per fiscal 
year for each review division. 
‘‘(2) INCLUSION.—The report under this sub-
section for a fiscal year shall include information on 
all previous cohorts for which the Secretary has not 
given a complete response on all human drug appli-
cations and supplements in the cohort.’’. 
(2) in subsection (b), by striking ‘‘2008’’ and 
inserting ‘‘2013’’; and 
(3) in subsection (d), by striking ‘‘2012’’ each 
place it appears and inserting ‘‘2017’’. 
SEC. 105. SUNSET DATES. 
(a) AUTHORIZATION.—Sections 735 and 736 (21 
U.S.C. 379g; 379h) are repealed October 1, 2017. 
(b) REPORTING REQUIREMENTS.—Section 736B (21 
U.S.C. 379h–2) is repealed January 31, 2018. 
(c) PREVIOUS SUNSET PROVISION.—Section 106 of 
the Prescription Drug User Fee Amendments of 2007 
(Title I of Public Law 110–85) is repealed. 
(d) TECHNICAL CLARIFICATIONS.— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(1) Effective September 30, 2007, section 508 
of the Prescription Drug User Fee Amendments Act 
of 2002 (Title V of Public Law 107–188) is re-
pealed. 
(2) Effective September 30, 2002, section 107 
of the Food and Drug Administration Modernization 
Act of 1997 (Public Law 105–115) is repealed. 
(3) Effective September 30, 1997, section 105 
of the Prescription Drug User Fee Act of 1992 
(Public Law 102–571) is repealed. 
SEC. 106. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2012, or the date of the enactment of this 
Act, whichever is later, except that fees under part 2 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act shall be assessed for all human drug 
applications received on or after October 1, 2012, regard-
less of the date of the enactment of this Act. 
SEC. 107. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 2 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act, as in effect on the day before 
the date of the enactment of this title, shall continue to 
be in effect with respect to human drug applications and 
supplements (as defined in such part as of such day) that 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
on or after October 1, 2007, but before October 1, 2012, 
were accepted by the Food and Drug Administration for 
filing with respect to assessing and collecting any fee re-
quired by such part for a fiscal year prior to fiscal year 
2012. 
TITLE II—MEDICAL DEVICE 
USER FEE AMENDMENTS OF 2012 
SEC. 201. SHORT TITLE; FINDINGS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Medical Device User Fee Amendments of 2012’’. 
(b) FINDINGS.—The Congress finds that the fees au-
thorized under the amendments made by this title will be 
dedicated toward expediting the process for the review of 
device applications and for assuring the safety and effec-
tiveness of devices, as set forth in the goals identified for 
purposes of part 3 of subchapter C of chapter VII of the 
Federal Food, Drug, and Cosmetic Act in the letters from 
the Secretary of Health and Human Services to the Chair-
man of the Committee on Health, Education, Labor, and 
Pensions of the Senate and the Chairman of the Com-
mittee on Energy and Commerce of the House of Rep-
resentatives, as set forth in the Congressional Record. 
SEC. 202. DEFINITIONS. 
Section 737 (21 U.S.C. 379i) is amended— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(1) in paragraph (9), by striking ‘‘incurred’’ 
after ‘‘expenses’’; 
(2) in paragraph (10), by striking ‘‘October 
2001’’ and inserting ‘‘October 2011’’; and 
(3) in paragraph (13), by striking ‘‘is required 
to register’’ and all that follows through the end of 
paragraph (13) and inserting the following: ‘‘is reg-
istered (or is required to register) with the Secretary 
under section 510 because such establishment is en-
gaged in the manufacture, preparation, propagation, 
compounding, or processing of a device.’’. 
SEC. 203. AUTHORITY TO ASSESS AND USE DEVICE FEES. 
(a) TYPES OF FEES.—Section 738(a) (21 U.S.C. 
379j(a)) is amended— 
(1) in paragraph (1), by striking ‘‘fiscal year 
2008’’ and inserting ‘‘fiscal year 2013’’; 
(2) in paragraph (2)(A)— 
(A) in the matter preceding clause (i)— 
(i) by striking ‘‘subsections (d) and 
(e)’’ and inserting ‘‘subsections (d), (e), 
and (f)’’; 
(ii) by striking ‘‘October 1, 2002’’ and 
inserting ‘‘October 1, 2012’’; and 
(iii) by striking ‘‘subsection (c)(1)’’ 
and inserting ‘‘subsection (c)’’; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(B) in clause (viii), by striking ‘‘1.84’’ and 
inserting ‘‘2’’; and 
(3) in paragraph (3)— 
(A) in subparagraph (A), by inserting 
‘‘and subsection (f)’’ after ‘‘subparagraph (B)’’; 
and 
(B) in subparagraph (C), by striking ‘‘ini-
tial registration’’ and all that follows through 
‘‘section 510.’’ and inserting ‘‘later of— 
‘‘(i) the initial or annual registration 
(as applicable) of the establishment under 
section 510; or 
‘‘(ii) the first business day after the 
date of enactment of an appropriations Act 
providing for the collection and obligation 
of fees for such year under this section.’’. 
(b) FEE AMOUNTS.—Section 738(b) (21 U.S.C. 
379j(b)) is amended to read as follows: 
‘‘(b) FEE AMOUNTS.— 
‘‘(1) IN GENERAL.—Subject to subsections (c), 
(d), (e), (f), and (i), for each of fiscal years 2013 
through 2017, fees under subsection (a) shall be de-
rived from the base fee amounts specified in para-
graph (2), to generate the total revenue amounts 
specified in paragraph (3). 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(2) BASE
FEE
AMOUNTS
SPECIFIED.—For 
purposes of paragraph (1), the base fee amounts 
specified in this paragraph are as follows: 
‘‘Fee Type 
Fiscal 
Year 
2013 
Fiscal 
Year 
2014 
Fiscal 
Year 
2015 
Fiscal 
Year 
2016 
Fiscal 
Year 
2017 
Premarket Application ........................
$248,000 
$252,960 
$258,019 
$263,180 
$268,443 
Establishment Registration ................
$2,575 
$3,200 
$3,750 
$3,872 
$3,872 
‘‘(3) TOTAL
REVENUE
AMOUNTS.—For pur-
poses of paragraph (1), the total revenue amounts 
specified in this paragraph are as follows: 
‘‘(A) $97,722,301 for fiscal year 2013. 
‘‘(B) $112,580,497 for fiscal year 2014. 
‘‘(C) $125,767,107 for fiscal year 2015. 
‘‘(D) $129,339,949 for fiscal year 2016. 
‘‘(E) $130,184,348 for fiscal year 2017.’’. 
(c) ANNUAL FEE SETTING; ADJUSTMENTS.—Section 
738(c) (21 U.S.C. 379j(c)) is amended— 
(1) in the subsection heading, by inserting ‘‘; 
ADJUSTMENTS’’ after ‘‘SETTING’’; 
(2) by striking paragraphs (1) and (2); 
(3) by redesignating paragraphs (3) and (4) as 
paragraphs (4) and (5), respectively; and 
(4) by inserting before paragraph (4), as so re-
designated, the following: 
‘‘(1) IN
GENERAL.—The Secretary shall, 60 
days before the start of each fiscal year after Sep-
tember 30, 2012, establish fees under subsection (a), 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
based on amounts specified under subsection (b) and 
the adjustments provided under this subsection, and 
publish such fees, and the rationale for any adjust-
ments to such fees, in the Federal Register. 
‘‘(2) INFLATION ADJUSTMENTS.— 
‘‘(A) ADJUSTMENT
TO
TOTAL
REVENUE 
AMOUNTS.—For fiscal year 2014 and each sub-
sequent fiscal year, the Secretary shall adjust 
the total revenue amount specified in subsection 
(b)(3) for such fiscal year by multiplying such 
amount by the applicable inflation adjustment 
under subparagraph (B) for such year. 
‘‘(B) APPLICABLE
INFLATION
ADJUST-
MENT TO TOTAL REVENUE AMOUNTS.—The ap-
plicable inflation adjustment for a fiscal year 
is— 
‘‘(i) for fiscal year 2014, the base in-
flation adjustment under subparagraph (C) 
for such fiscal year; and 
‘‘(ii) for fiscal year 2015 and each 
subsequent fiscal year, the product of— 
‘‘(I) the base inflation adjust-
ment under subparagraph (C) for 
such fiscal year; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(II) the product of the base in-
flation adjustment under subpara-
graph (C) for each of the fiscal years 
preceding such fiscal year, beginning 
with fiscal year 2014. 
‘‘(C) BASE
INFLATION
ADJUSTMENT
TO 
TOTAL REVENUE AMOUNTS.— 
‘‘(i) IN GENERAL.—Subject to further 
adjustment under clause (ii), the base in-
flation adjustment for a fiscal year is the 
sum of one plus— 
‘‘(I) the average annual percent 
change in the cost, per full-time equiv-
alent position of the Food and Drug 
Administration, of all personnel com-
pensation and benefits paid with re-
spect to such positions for the first 3 
years of the preceding 4 fiscal years, 
multiplied by 0.60; and 
‘‘(II) the average annual percent 
change that occurred in the Consumer 
Price Index for urban consumers 
(Washington-Baltimore, DC–MD–VA– 
WV; Not Seasonally Adjusted; All 
items; Annual Index) for the first 3 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
years of the preceding 4 years of 
available data multiplied by 0.40. 
‘‘(ii) LIMITATIONS.—For purposes of 
subparagraph (B), if the base inflation ad-
justment for a fiscal year under clause 
(i)— 
‘‘(I) is less than 1, such adjust-
ment shall be considered to be equal 
to 1; or 
‘‘(II) is greater than 1.04, such 
adjustment shall be considered to be 
equal to 1.04. 
‘‘(D) 
ADJUSTMENT
TO
BASE
FEE 
AMOUNTS.—For each of fiscal years 2014 
through 2017, the base fee amounts specified in 
subsection (b)(2) shall be adjusted as needed, 
on a uniform proportionate basis, to generate 
the total revenue amounts under subsection 
(b)(3), as adjusted for inflation under subpara-
graph (A). 
‘‘(3) VOLUME-BASED ADJUSTMENTS TO ESTAB-
LISHMENT REGISTRATION BASE FEES.—For each of 
fiscal years 2014 through 2017, after the base fee 
amounts specified in subsection (b)(2) are adjusted 
under paragraph (2)(D), the base establishment reg-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
istration fee amounts specified in such subsection 
shall be further adjusted, as the Secretary estimates 
is necessary in order for total fee collections for such 
fiscal year to generate the total revenue amounts, as 
adjusted under paragraph (2).’’. 
(d) FEE WAIVER OR REDUCTION.—Section 738 (21 
U.S.C. 379j) is amended by— 
(1) redesignating subsections (f) through (k) as 
subsections (g) through (l), respectively; and 
(2) by inserting after subsection (e) the fol-
lowing new subsection (f): 
‘‘(f) FEE WAIVER OR REDUCTION.— 
‘‘(1) IN GENERAL.—The Secretary may, at the 
Secretary’s sole discretion, grant a waiver or reduc-
tion of fees under subsection (a)(2) or (a)(3) if the 
Secretary finds that such waiver or reduction is in 
the interest of public health. 
‘‘(2) LIMITATION.—The sum of all fee waivers 
or reductions granted by the Secretary in any fiscal 
year under paragraph (1) shall not exceed 2 percent 
of the total fee revenue amounts established for such 
year under subsection (c). 
‘‘(3) DURATION.—The authority provided by 
this subsection terminates October 1, 2017.’’. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(e) CONDITIONS.—Section 738(h)(1)(A) (21 U.S.C. 
379j(h)(1)(A)), as redesignated by subsection (d)(1), is 
amended by striking ‘‘$205,720,000’’ and inserting 
‘‘$280,587,000’’. 
(f) CREDITING AND AVAILABILITY OF FEES.—Sec-
tion 738(i) (21 U.S.C. 379j(i)), as redesignated by sub-
section (d)(1), is amended— 
(1) in paragraph (1), by striking ‘‘Fees author-
ized’’ and inserting ‘‘Subject to paragraph (2)(C), 
fees authorized’’; 
(2) in paragraph (2)— 
(A) in subparagraph (A)— 
(i) in clause (i), by striking ‘‘shall be 
retained’’ and inserting ‘‘subject to sub-
paragraph (C), shall be collected and avail-
able’’; and 
(ii) in clause (ii)— 
(I) by striking ‘‘collected and’’ 
after ‘‘shall only be’’; and 
(II) by striking ‘‘fiscal year 
2002’’ and inserting ‘‘fiscal year 
2009’’; and 
(B) by adding at the end, the following: 
‘‘(C) PROVISION
FOR
EARLY
YEAR
PAY-
MENTS.—Payment of fees authorized under this 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
section for a fiscal year, prior to the due date 
for such fees, may be accepted by the Secretary 
in accordance with authority provided in ad-
vance in a prior year appropriations Act.’’; 
(3) in paragraph (3), by amending to read as 
follows: 
‘‘(3) AUTHORIZATIONS OF APPROPRIATIONS.— 
For each of the fiscal years 2013 through 2017, 
there is authorized to be appropriated for fees under 
this section an amount equal to the total revenue 
amount specified under subsection (b)(3) for the fis-
cal year, as adjusted under subsection (c) and, for 
fiscal year 2017 only, as further adjusted under 
paragraph (4).’’; and 
(4) in paragraph (4)— 
(A) by striking ‘‘fiscal years 2008, 2009, 
and 2010’’ and inserting ‘‘fiscal years 2013, 
2014, and 2015’’; 
(B) by striking ‘‘fiscal year 2011’’ and in-
serting ‘‘fiscal year 2016’’; 
(C) by striking ‘‘June 30, 2011’’ and in-
serting ‘‘June 30, 2016’’; 
(D) by striking ‘‘the amount of fees speci-
fied in aggregate in’’ and inserting ‘‘the cumu-
lative amount appropriated pursuant to’’; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
(E) by striking ‘‘aggregate amount in’’ be-
fore ‘‘excess shall be credited’’; and 
(F) by striking ‘‘fiscal year 2012’’ and in-
serting ‘‘fiscal year 2017’’. 
(g) 
CONFORMING
AMENDMENT.—Section 
515(c)(4)(A) (21 U.S.C. 360e(c)(4)(A)) is amended by 
striking ‘‘738(g)’’ and inserting ‘‘738(h)’’. 
SEC. 204. REAUTHORIZATION; REPORTING REQUIREMENTS. 
(a) 
REAUTHORIZATION.—Section 
738A(b) 
(21 
U.S.C. 379j–1(b)) is amended— 
(1) in paragraph (1), by striking ‘‘2012’’ and 
inserting ‘‘2017’’; and 
(2) in paragraph (5), by striking ‘‘2012’’ and 
inserting ‘‘2017’’. 
(b) PERFORMANCE REPORTS.—Section 738A(a) (21 
U.S.C. 379j–1(a)) is amended— 
(1) by striking paragraph (1) and inserting the 
following: 
‘‘(1) PERFORMANCE REPORT.— 
‘‘(A) IN GENERAL.—Beginning with fiscal 
year 2013, for each fiscal year for which fees 
are collected under this part, the Secretary 
shall prepare and submit to the Committee on 
Health, Education, Labor, and Pensions of the 
Senate and the Committee on Energy and Com-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
merce of the House of Representatives annual 
reports concerning the progress of the Food 
and Drug Administration in achieving the goals 
identified in the letters described in section 
201(b) of the Medical Device User Fee Amend-
ments of 2012 during such fiscal year and the 
future plans of the Food and Drug Administra-
tion for meeting the goals. 
‘‘(B) PUBLICATION.—With regard to infor-
mation to be reported by the Food and Drug 
Administration to industry on a quarterly and 
annual basis pursuant to the letters described 
in section 201(b) of the Medical Device User 
Fee Amendments Act of 2012, the Secretary 
shall make such information publicly available 
on the Internet Website of the Food and Drug 
Administration not later than 60 days after the 
end of each quarter or 120 days after the end 
of each fiscal year, respectively, to which such 
information applies. This information shall in-
clude the status of the independent assessment 
identified in the letters described in such sec-
tion 201(b). 
‘‘(C) UPDATES.—The Secretary shall in-
clude in each report under subparagraph (A) 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00034
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
information on all previous cohorts for which 
the Secretary has not given a complete response 
on all device premarket applications and re-
ports, supplements, and premarket notifications 
in the cohort.’’; and 
(2) in paragraph (2), by striking ‘‘2008 
through 2012’’ and inserting ‘‘2013 through 2017’’. 
SEC. 205. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 3 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in 
effect on the day before the date of the enactment of this 
title, shall continue to be in effect with respect to the sub-
missions listed in section 738(a)(2)(A) of such Act (as de-
fined in such part as of such day) that on or after October 
1, 2007, but before October 1, 2012, were accepted by 
the Food and Drug Administration for filing with respect 
to assessing and collecting any fee required by such part 
for a fiscal year prior to fiscal year 2013. 
SEC. 206. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2012, or the date of the enactment of this 
Act, whichever is later, except that fees under part 3 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act shall be assessed for all submissions list-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00035
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
ed in section 738(a)(2)(A) of such Act received on or after 
October 1, 2012, regardless of the date of the enactment 
of this Act. 
SEC. 207. SUNSET CLAUSE. 
(a) IN GENERAL.—Sections 737 and 738 of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 739i; 739j) 
shall cease to be effective October 1, 2017. Section 738A 
(21 U.S.C. 739j–1) of the Federal Food, Drug, and Cos-
metic Act (regarding reauthorization and reporting re-
quirements) are repealed January 31, 2018. 
(b) PREVIOUS SUNSET PROVISION.—Section 217 of 
the Medical Device User Fee Amendments of 2007 (Title 
II of Public Law 110–85) is repealed. 
(c) TECHNICAL
CLARIFICATION.—Effective Sep-
tember 30, 2007, section 107 of the Medical Device User 
Fee and Modernization Act of 2002 (Public Law 107– 
250) is repealed. 
SEC. 208. STREAMLINED HIRING AUTHORITY TO SUPPORT 
ACTIVITIES RELATED TO THE PROCESS FOR 
THE REVIEW OF DEVICE APPLICATIONS. 
Subchapter A of chapter VII (21 U.S.C. 371 et seq.) 
is amended by inserting after section 713 the following 
new section: 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00036
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘SEC. 714. STREAMLINED HIRING AUTHORITY. 
‘‘(a) IN GENERAL.—In addition to any other per-
sonnel authorities under other provisions of law, the Sec-
retary may, without regard to the provisions of title 5, 
United States Code, governing appointments in the com-
petitive service, appoint employees to positions in the Food 
and Drug Administration to perform, administer, or sup-
port activities described in subsection (b), if the Secretary 
determines that such appointments are needed to achieve 
the objectives specified in subsection (c). 
‘‘(b) ACTIVITIES DESCRIBED.—The activities de-
scribed in this subsection are activities under this Act re-
lated to the process for the review of device applications 
(as defined in section 737(8)). 
‘‘(c) OBJECTIVES SPECIFIED.—The objectives speci-
fied in this subsection are with respect to the activities 
under subsection (b)(1), the goals referred to in section 
738A(a)(1). 
‘‘(d) INTERNAL CONTROLS.—The Secretary shall in-
stitute appropriate internal controls for appointments 
under this section. 
‘‘(e) SUNSET.—The authority to appoint employees 
under this section shall terminate on the date that is three 
years after the date of enactment of this section.’’. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
TITLE III—FEES RELATING TO 
GENERIC DRUGS 
SEC. 301. SHORT TITLE. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Generic Drug User Fee Amendments of 2012’’. 
(b) FINDING.—The Congress finds that the fees au-
thorized by the amendments made in this title will be dedi-
cated to human generic drug activities, as set forth in the 
goals identified for purposes of part 7 of subchapter C 
of chapter VII of the Federal Food, Drug, and Cosmetic 
Act, in the letters from the Secretary of Health and 
Human Services to the Chairman of the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
the Chairman of the Committee on Energy and Commerce 
of the House of Representatives, as set forth in the Con-
gressional Record. 
SEC. 302. AUTHORITY TO ASSESS AND USE HUMAN GE-
NERIC DRUG FEES. 
Subchapter C of chapter VII (21 U.S.C. 379f et seq.) 
is amended by adding at the end the following: 
‘‘PART 7—FEES RELATING TO GENERIC DRUGS 
‘‘SEC. 744A. DEFINITIONS. 
‘‘For purposes of this part: 
‘‘(1) The term ‘abbreviated new drug applica-
tion’— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(A) means an application submitted 
under section 505(j), an abbreviated application 
submitted under section 507 (as in effect on the 
day before the date of enactment of the Food 
and Drug Administration Modernization Act of 
1997), or an abbreviated new drug application 
submitted pursuant to regulations in effect 
prior to the implementation of the Drug Price 
Competition and Patent Term Restoration Act 
of 1984; and 
‘‘(B) does not include an application for a 
positron emission tomography drug. 
‘‘(2) The term ‘active pharmaceutical ingre-
dient’ means— 
‘‘(A) a substance, or a mixture when the 
substance is unstable or cannot be transported 
on its own, intended— 
‘‘(i) to be used as a component of a 
drug; and 
‘‘(ii) to furnish pharmacological activ-
ity or other direct effect in the diagnosis, 
cure, mitigation, treatment, or prevention 
of disease, or to affect the structure or any 
function of the human body; or 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) a substance intended for final crys-
tallization, purification, or salt formation, or 
any combination of those activities, to become a 
substance or mixture described in subparagraph 
(A). 
‘‘(3) The term ‘adjustment factor’ means a fac-
tor applicable to a fiscal year that is the Consumer 
Price Index for all urban consumers (all items; 
United States city average) for October of the pre-
ceding fiscal year divided by such Index for October 
2011. 
‘‘(4) The term ‘affiliate’ means a business enti-
ty that has a relationship with a second business en-
tity if, directly or indirectly— 
‘‘(A) one business entity controls, or has 
the power to control, the other business entity; 
or 
‘‘(B) a third party controls, or has power 
to control, both of the business entities. 
‘‘(5)(A) The term ‘facility’— 
‘‘(i) means a business or other entity— 
‘‘(I) under one management, either di-
rect or indirect; and 
‘‘(II) at one geographic location or ad-
dress engaged in manufacturing or proc-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
essing an active pharmaceutical ingredient 
or a finished dosage form; and 
‘‘(ii) does not include a business or other 
entity whose only manufacturing or processing 
activities are one or more of the following: re-
packaging, relabeling, or testing. 
‘‘(B) For purposes of subparagraph (A), sepa-
rate buildings within close proximity are considered 
to be at one geographic location or address if the ac-
tivities in them are— 
‘‘(i) closely related to the same business 
enterprise; 
‘‘(ii) under the supervision of the same 
local management; and 
‘‘(iii) capable of being inspected by the 
Food and Drug Administration during a single 
inspection. 
‘‘(C) If a business or other entity would meet 
the definition of a facility under this paragraph but 
for being under multiple management, the business 
or other entity is deemed to constitute multiple fa-
cilities, one per management entity, for purposes of 
this paragraph. 
‘‘(6) The term ‘finished dosage form’ means— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(A) a drug product in the form in which 
it will be administered to a patient, such as a 
tablet, capsule, solution, or topical application; 
‘‘(B) a drug product in a form in which re-
constitution is necessary prior to administration 
to a patient, such as oral suspensions or 
lyophilized powders; or 
‘‘(C) any combination of an active pharma-
ceutical ingredient with another component of a 
drug product for purposes of production of a 
drug product described in subparagraph (A) or 
(B). 
‘‘(7) The term ‘generic drug submission’ means 
an abbreviated new drug application, an amendment 
to an abbreviated new drug application, or a prior 
approval supplement to an abbreviated new drug ap-
plication. 
‘‘(8) The term ‘human generic drug activities’ 
means the following activities of the Secretary asso-
ciated with generic drugs and inspection of facilities 
associated with generic drugs: 
‘‘(A) The activities necessary for the re-
view of generic drug submissions, including re-
view of drug master files referenced in such 
submissions. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) The issuance of— 
‘‘(i) approval letters which approve 
abbreviated new drug applications or sup-
plements to such applications; or 
‘‘(ii) complete response letters which 
set forth in detail the specific deficiencies 
in such applications and, where appro-
priate, the actions necessary to place such 
applications in condition for approval. 
‘‘(C) The issuance of letters related to 
Type II active pharmaceutical drug master files 
which— 
‘‘(i) set forth in detail the specific de-
ficiencies in such submissions, and where 
appropriate, the actions necessary to re-
solve those deficiencies; or 
‘‘(ii) document that no deficiencies 
need to be addressed. 
‘‘(D) Inspections related to generic drugs. 
‘‘(E) Monitoring of research conducted in 
connection with the review of generic drug sub-
missions and drug master files. 
‘‘(F) Postmarket safety activities with re-
spect to drugs approved under abbreviated new 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(9) The term ‘positron emission tomography 
drug’ has the meaning given to the term ‘com-
pounded positron emission tomography drug’ in sec-
tion 201(ii), except that paragraph (1)(B) of such 
section shall not apply. 
‘‘(10) The term ‘prior approval supplement’ 
means a request to the Secretary to approve a 
change in the drug substance, drug product, produc-
tion process, quality controls, equipment, or facilities 
covered by an approved abbreviated new drug appli-
cation when that change has a substantial potential 
to have an adverse effect on the identity, strength, 
quality, purity, or potency of the drug product as 
these factors may relate to the safety or effective-
ness of the drug product. 
‘‘(11) The term ‘resources allocated for human 
generic drug activities’ means the expenses for— 
‘‘(A) officers and employees of the Food 
and Drug Administration, contractors of the 
Food and Drug Administration, advisory com-
mittees, and costs related to such officers and 
employees and to contracts with such contrac-
tors; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00045
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) management of information, and the 
acquisition, maintenance, and repair of com-
puter resources; 
‘‘(C) leasing, maintenance, renovation, and 
repair of facilities and acquisition, maintenance, 
and repair of fixtures, furniture, scientific 
equipment, and other necessary materials and 
supplies; and 
‘‘(D) collecting fees under subsection (a) 
and accounting for resources allocated for the 
review of abbreviated new drug applications and 
supplements and inspection related to generic 
drugs. 
‘‘(12) The term ‘Type II active pharmaceutical 
ingredient drug master file’ means a submission of 
information to the Secretary by a person that in-
tends to authorize the Food and Drug Administra-
tion to reference the information to support approval 
of a generic drug submission without the submitter 
having to disclose the information to the generic 
drug submission applicant. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00046
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘SEC. 744B. AUTHORITY TO ASSESS AND USE HUMAN GE-
NERIC DRUG FEES. 
‘‘(a) TYPES
OF FEES.—Beginning in fiscal year 
2013, the Secretary shall assess and collect fees in accord-
ance with this section as follows: 
‘‘(1) ONE-TIME
BACKLOG
FEE
FOR
ABBRE-
VIATED NEW DRUG APPLICATIONS PENDING ON OC-
TOBER 1, 2012.— 
‘‘(A) IN
GENERAL.—Each person that 
owns an abbreviated new drug application that 
is pending on October 1, 2012, and that has 
not received a tentative approval prior to that 
date, shall be subject to a fee for each such ap-
plication, as calculated under subparagraph 
(B). 
‘‘(B) METHOD OF FEE AMOUNT CALCULA-
TION.—The amount of each one-time backlog 
fee shall be calculated by dividing $50,000,000 
by the total number of abbreviated new drug 
applications pending on October 1, 2012, that 
have not received a tentative approval as of that 
date. 
‘‘(C) NOTICE.—Not later than October 31, 
2012, the Secretary shall cause to be published 
in the Federal Register a notice announcing the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00047
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
amount of the fee required by subparagraph 
(A). 
‘‘(D) FEE DUE DATE.—The fee required 
by subparagraph (A) shall be due no later than 
30 calendar days after the date of the publica-
tion of the notice specified in subparagraph (C). 
‘‘(2) DRUG MASTER FILE FEE.— 
‘‘(A) IN
GENERAL.—Each person that 
owns a Type II active pharmaceutical ingre-
dient drug master file that is referenced on or 
after October 1, 2012, in a generic drug sub-
mission by any initial letter of authorization 
shall be subject to a drug master file fee. 
‘‘(B) ONE-TIME
PAYMENT.—If a person 
has paid a drug master file fee for a Type II 
active pharmaceutical ingredient drug master 
file, the person shall not be required to pay a 
subsequent drug master file fee when that Type 
II active pharmaceutical ingredient drug master 
file is subsequently referenced in generic drug 
submissions. 
‘‘(C) NOTICE.— 
‘‘(i) FISCAL
YEAR
2013.—Not later 
than October 31, 2012, the Secretary shall 
cause to be published in the Federal Reg-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00048
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
ister a notice announcing the amount of 
the drug master file fee for fiscal year 
2013. 
‘‘(ii) FISCAL
YEAR
2014
THROUGH 
2017.—Not later than 60 days before the 
start of each of fiscal years 2014 through 
2017, the Secretary shall cause to be pub-
lished in the Federal Register the amount 
of the drug master file fee established by 
this paragraph for such fiscal year. 
‘‘(D) AVAILABILITY FOR REFERENCE.— 
‘‘(i) IN
GENERAL.—Subject to sub-
section (g)(2)(C), for a generic drug sub-
mission to reference a Type II active phar-
maceutical ingredient drug master file, the 
drug master file must be deemed available 
for reference by the Secretary. 
‘‘(ii) CONDITIONS.—A drug master 
file shall be deemed available for reference 
by the Secretary if— 
‘‘(I) the person that owns a Type 
II active pharmaceutical ingredient 
drug master file has paid the fee re-
quired under subparagraph (A) within 
20 calendar days after the applicable 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00049
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
due date under subparagraph (E); 
and 
‘‘(II) the drug master file has not 
failed an initial completeness assess-
ment by the Secretary, in accordance 
with criteria to be published by the 
Secretary. 
‘‘(iii) 
LIST.—The 
Secretary 
shall 
make publicly available on the Internet 
Web site of the Food and Drug Adminis-
tration a list of the drug master file num-
bers that correspond to drug master files 
that have successfully undergone an initial 
completeness assessment, in accordance 
with criteria to be published by the Sec-
retary, and are available for reference. 
‘‘(E) FEE DUE DATE.— 
‘‘(i) IN GENERAL.—Subject to clause 
(ii), a drug master file fee shall be due no 
later than the date on which the first ge-
neric drug submission is submitted that 
references the associated Type II active 
pharmaceutical ingredient drug master file. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00050
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(ii) LIMITATION.—No fee shall be 
due under subparagraph (A) for a fiscal 
year until the later of— 
‘‘(I) 30 calendar days after publi-
cation of the notice provided for in 
clause (i) or (ii) of subparagraph (C), 
as applicable; or 
‘‘(II) 30 calendar days after the 
date of enactment of an appropria-
tions Act providing for the collection 
and obligation of fees under this sec-
tion. 
‘‘(3) ABBREVIATED
NEW
DRUG
APPLICATION 
AND PRIOR APPROVAL SUPPLEMENT FILING FEE.— 
‘‘(A) IN GENERAL.—Each applicant that 
submits, on or after October 1, 2012, an abbre-
viated new drug application or a prior approval 
supplement to an abbreviated new drug applica-
tion shall be subject to a fee for each such sub-
mission in the amount established under sub-
section (d). 
‘‘(B) NOTICE.— 
‘‘(i) FISCAL
YEAR
2013.—Not later 
than October 31, 2012, the Secretary shall 
cause to be published in the Federal Reg-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00051
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
ister a notice announcing the amount of 
the fees under subparagraph (A) for fiscal 
year 2013. 
‘‘(ii) FISCAL
YEARS
2014
THROUGH 
2017.—Not later than 60 days before the 
start of each of fiscal years 2014 through 
2017, the Secretary shall cause to be pub-
lished in the Federal Register the amount 
of the fees under subparagraph (A) for 
such fiscal year. 
‘‘(C) FEE DUE DATE.— 
‘‘(i) IN
GENERAL.—Except as pro-
vided in clause (ii), the fees required by 
subparagraphs (A) and (F) shall be due no 
later than the date of submission of the 
abbreviated new drug application or prior 
approval supplement for which such fee ap-
plies. 
‘‘(ii) SPECIAL RULE FOR 2013.—For 
fiscal year 2013, such fees shall be due on 
the later of— 
‘‘(I) the date on which the fee is 
due under clause (i); 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00052
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(II) 30 calendar days after pub-
lication of the notice referred to in 
subparagraph (B)(i); or 
‘‘(III) if an appropriations Act is 
not enacted providing for the collec-
tion and obligation of fees under this 
section by the date of submission of 
the application or prior approval sup-
plement for which the fees under sub-
paragraphs (A) and (F) apply, 30 cal-
endar days after the date that such an 
appropriations Act is enacted. 
‘‘(D) REFUND OF FEE IF ABBREVIATED 
NEW DRUG APPLICATION IS NOT CONSIDERED 
TO
HAVE
BEEN
RECEIVED.—The Secretary 
shall refund 75 percent of the fee paid under 
subparagraph (A) for any abbreviated new drug 
application or prior approval supplement to an 
abbreviated new drug application that the Sec-
retary considers not to have been received with-
in the meaning of section 505(j)(5)(A) for a 
cause other than failure to pay fees. 
‘‘(E) FEE FOR AN APPLICATION THE SEC-
RETARY CONSIDERS NOT TO HAVE BEEN RE-
CEIVED, OR THAT HAS BEEN WITHDRAWN.—An 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00053
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
abbreviated new drug application or prior ap-
proval supplement that was submitted on or 
after October 1, 2012, and that the Secretary 
considers not to have been received, or that has 
been withdrawn, shall, upon resubmission of the 
application or a subsequent new submission fol-
lowing the applicant’s withdrawal of the appli-
cation, be subject to a full fee under subpara-
graph (A). 
‘‘(F) ADDITIONAL FEE FOR ACTIVE PHAR-
MACEUTICAL
INGREDIENT
INFORMATION
NOT 
INCLUDED BY REFERENCE TO TYPE II ACTIVE 
PHARMACEUTICAL INGREDIENT DRUG MASTER 
FILE.—An applicant that submits a generic 
drug submission on or after October 1, 2012, 
shall pay a fee, in the amount determined under 
subsection (d)(3), in addition to the fee re-
quired under subparagraph (A), if— 
‘‘(i) such submission contains infor-
mation concerning the manufacture of an 
active pharmaceutical ingredient at a facil-
ity by means other than reference by a let-
ter of authorization to a Type II active 
pharmaceutical drug master file; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00054
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(ii) a fee in the amount equal to the 
drug master file fee established in para-
graph (2) has not been previously paid 
with respect to such information. 
‘‘(4) GENERIC DRUG FACILITY FEE AND ACTIVE 
PHARMACEUTICAL INGREDIENT FACILITY FEE.— 
‘‘(A) IN
GENERAL.—Facilities identified, 
or intended to be identified, in at least one ge-
neric drug submission that is pending or ap-
proved to produce a finished dosage form of a 
human generic drug or an active pharma-
ceutical ingredient contained in a human ge-
neric drug shall be subject to fees as follows: 
‘‘(i) GENERIC DRUG FACILITY.—Each 
person that owns a facility which is identi-
fied or intended to be identified in at least 
one generic drug submission that is pend-
ing or approved to produce one or more 
finished dosage forms of a human generic 
drug shall be assessed an annual fee for 
each such facility. 
‘‘(ii) ACTIVE
PHARMACEUTICAL
IN-
GREDIENT
FACILITY.—Each person that 
owns a facility which produces, or which is 
pending review to produce, one or more ac-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00055
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
tive pharmaceutical ingredients identified, 
or intended to be identified, in at least one 
generic drug submission that is pending or 
approved or in a Type II active pharma-
ceutical ingredient drug master file ref-
erenced in such a generic drug submission, 
shall be assessed an annual fee for each 
such facility. 
‘‘(iii) FACILITIES
PRODUCING
BOTH 
ACTIVE
PHARMACEUTICAL
INGREDIENTS 
AND
FINISHED
DOSAGE
FORMS.—Each 
person that owns a facility identified, or 
intended to be identified, in at least one 
generic drug submission that is pending or 
approved to produce both one or more fin-
ished dosage forms subject to clause (i) 
and one or more active pharmaceutical in-
gredients subject to clause (ii) shall be 
subject to fees under both such clauses for 
that facility. 
‘‘(B) AMOUNT.—The amount of fees estab-
lished under subparagraph (A) shall be estab-
lished under subsection (d). 
‘‘(C) NOTICE.— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00056
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
that such an appropriations Act is en-
acted. 
‘‘(ii) FISCAL
YEARS
2014
THROUGH 
2017.—For each of fiscal years 2014 
through 2017, the fees under subpara-
graph (A) for such fiscal year shall be due 
on the later of— 
‘‘(I) the first business day on or 
after October 1 of each such year; or 
‘‘(II) the first business day after 
the enactment of an appropriations 
Act providing for the collection and 
obligation of fees under this section 
for such year. 
‘‘(5) DATE OF SUBMISSION.—For purposes of 
this part, a generic drug submission or Type II 
pharmaceutical master file is deemed to be ‘sub-
mitted’ to the Food and Drug Administration— 
‘‘(A) if it is submitted via a Food and 
Drug Administration electronic gateway, on the 
day when transmission to that electronic gate-
way is completed, except that a submission or 
master file that arrives on a weekend, Federal 
holiday, or day when the Food and Drug Ad-
ministration office that will review that submis-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00058
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
sion is not otherwise open for business shall be 
deemed to be submitted on the next day when 
that office is open for business; and 
‘‘(B) if it is submitted in physical media 
form, on the day it arrives at the appropriate 
designated document room of the Food and 
Drug Administration. 
‘‘(b) FEE REVENUE AMOUNTS.— 
‘‘(1) IN GENERAL.— 
‘‘(A) FISCAL YEAR 2013.—For fiscal year 
2013, fees under subsection (a) shall be estab-
lished to generate a total estimated revenue 
amount under such subsection of $299,000,000. 
Of that amount— 
‘‘(i) $50,000,000 shall be generated 
by the one-time backlog fee for generic 
drug applications pending on October 1, 
2012, established in subsection (a)(1); and 
‘‘(ii) $249,000,000 shall be generated 
by the fees under paragraphs (2) through 
(4) of subsection (a). 
‘‘(B) FISCAL YEARS 2014 THROUGH 2017.— 
For each of the fiscal years 2014 through 2017, 
fees under paragraphs (2) through (4) of sub-
section (a) shall be established to generate a 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00059
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
total estimated revenue amount under such sub-
section that is equal to $299,000,000, as ad-
justed pursuant to subsection (c). 
‘‘(2) TYPES
OF
FEES.—In establishing fees 
under paragraph (1) to generate the revenue 
amounts specified in paragraph (1)(A)(ii) for fiscal 
year 2013 and paragraph (1)(B) for each of fiscal 
years 2014 through 2017, such fees shall be derived 
from the fees under paragraphs (2) through (4) of 
subsection (a) as follows: 
‘‘(A) 6 percent shall be derived from fees 
under subsection (a)(2) (relating to drug mas-
ter files). 
‘‘(B) 24 percent shall be derived from fees 
under subsection (a)(3) (relating to abbreviated 
new drug applications and supplements). The 
amount of a fee for a prior approval supplement 
shall be half the amount of the fee for an ab-
breviated new drug application. 
‘‘(C) 56 percent shall be derived from fees 
under subsection (a)(4)(A)(i) (relating to ge-
neric drug facilities). The amount of the fee for 
a facility located outside the United States and 
its territories and possessions shall be not less 
than $15,000 and not more than $30,000 high-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00060
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
er than the amount of the fee for a facility lo-
cated in the United States and its territories 
and possessions, as determined by the Secretary 
on the basis of data concerning the difference 
in cost between inspections of facilities located 
in the United States, including its territories 
and possessions, and those located outside of 
the United States and its territories and posses-
sions. 
‘‘(D) 14 percent shall be derived from fees 
under subsection (a)(4)(A)(ii) (relating to active 
pharmaceutical 
ingredient 
facilities). 
The 
amount of the fee for a facility located outside 
the United States and its territories and posses-
sions shall be not less than $15,000 and not 
more than $30,000 higher than the amount of 
the fee for a facility located in the United 
States, including its territories and possessions, 
as determined by the Secretary on the basis of 
data concerning the difference in cost between 
inspections of facilities located in the United 
States and its territories and possessions and 
those located outside of the United States and 
its territories and possessions. 
‘‘(c) ADJUSTMENTS.— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00061
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(1) INFLATION ADJUSTMENT.—For fiscal year 
2014 and subsequent fiscal years, the revenues es-
tablished in subsection (b) shall be adjusted by the 
Secretary by notice, published in the Federal Reg-
ister, for a fiscal year, by an amount equal to the 
sum of— 
‘‘(A) one; 
‘‘(B) the average annual percent change in 
the cost, per full-time equivalent position of the 
Food and Drug Administration, of all personnel 
compensation and benefits paid with respect to 
such positions for the first 3 years of the pre-
ceding 4 fiscal years multiplied by the propor-
tion of personnel compensation and benefits 
costs to total costs of human generic drug ac-
tivities for the first 3 years of the preceding 4 
fiscal years; and 
‘‘(C) the average annual percent change 
that occurred in the Consumer Price Index for 
urban consumers (Washington-Baltimore, DC– 
MD–VA–WV; Not Seasonally Adjusted; All 
items; Annual Index) for the first 3 years of the 
preceding 4 years of available data multiplied 
by the proportion of all costs other than per-
sonnel compensation and benefits costs to total 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00062
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
costs of human generic drug activities for the 
first 3 years of the preceding 4 fiscal years. 
The adjustment made each fiscal year under this 
subsection shall be added on a compounded basis to 
the sum of all adjustments made each fiscal year 
after fiscal year 2013 under this subsection. 
‘‘(2) FINAL
YEAR
ADJUSTMENT.—For fiscal 
year 2017, the Secretary may, in addition to adjust-
ments under paragraph (1), further increase the fee 
revenues and fees established in subsection (b) if 
such an adjustment is necessary to provide for not 
more than 3 months of operating reserves of carry-
over user fees for human generic drug activities for 
the first 3 months of fiscal year 2018. Such fees 
may only be used in fiscal year 2018. If such an ad-
justment is necessary, the rationale for the amount 
of the increase shall be contained in the annual no-
tice establishing fee revenues and fees for fiscal year 
2017. If the Secretary has carryover balances for 
such activities in excess of 3 months of such oper-
ating reserves, the adjustment under this subpara-
graph shall not be made. 
‘‘(d) ANNUAL FEE SETTING.— 
‘‘(1) FISCAL
YEAR
2013.—For fiscal year 
2013— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00063
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(A) the Secretary shall establish, by Octo-
ber 31, 2012, the one-time generic drug backlog 
fee for generic drug applications pending on Oc-
tober 1, 2012, the drug master file fee, the ab-
breviated new drug application fee, and the 
prior approval supplement fee under subsection 
(a), based on the revenue amounts established 
under subsection (b); and 
‘‘(B) the Secretary shall establish, not 
later than 45 days after the date to comply 
with the requirement for identification of facili-
ties in subsection (f)(2), the generic drug facil-
ity fee and active pharmaceutical ingredient fa-
cility fee under subsection (a) based on the rev-
enue amounts established under subsection (b). 
‘‘(2) FISCAL YEARS 2014 THROUGH 2017.—Not 
more than 60 days before the first day of each of 
fiscal years 2014 through 2017, the Secretary shall 
establish the drug master file fee, the abbreviated 
new drug application fee, the prior approval supple-
ment fee, the generic drug facility fee, and the active 
pharmaceutical ingredient facility fee under sub-
section (a) for such fiscal year, based on the revenue 
amounts established under subsection (b) and the 
adjustments provided under subsection (c). 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00064
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(3) FEE
FOR
ACTIVE
PHARMACEUTICAL
IN-
GREDIENT INFORMATION NOT INCLUDED BY REF-
ERENCE TO TYPE II ACTIVE PHARMACEUTICAL IN-
GREDIENT DRUG MASTER FILE.—In establishing the 
fees under paragraphs (1) and (2), the amount of 
the fee under subsection (a)(3)(F) shall be deter-
mined by multiplying— 
‘‘(A) the sum of— 
‘‘(i) the total number of such active 
pharmaceutical ingredients in such submis-
sion; and 
‘‘(ii) for each such ingredient that is 
manufactured at more than one such facil-
ity, the total number of such additional fa-
cilities; and 
‘‘(B) the amount equal to the drug master 
file fee established in subsection (a)(2) for such 
submission. 
‘‘(e) LIMIT.—The total amount of fees charged, as 
adjusted under subsection (c), for a fiscal year may not 
exceed the total costs for such fiscal year for the resources 
allocated for human generic drug activities. 
‘‘(f) IDENTIFICATION OF FACILITIES.— 
‘‘(1) PUBLICATION OF NOTICE; DEADLINE FOR 
COMPLIANCE.—Not later than October 1, 2012, the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00065
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
Secretary shall cause to be published in the Federal 
Register a notice requiring each person that owns a 
facility described in subsection (a)(4)(A), or a site or 
organization required to be identified by paragraph 
(4), to submit to the Secretary information on the 
identity of each such facility, site, or organization. 
The notice required by this paragraph shall specify 
the type of information to be submitted and the 
means and format for submission of such informa-
tion. 
‘‘(2) REQUIRED
SUBMISSION
OF
FACILITY 
IDENTIFICATION.—Each person that owns a facility 
described in subsection (a)(4)(A) or a site or organi-
zation required to be identified by paragraph (4) 
shall submit to the Secretary the information re-
quired under this subsection each year. Such infor-
mation shall— 
‘‘(A) for fiscal year 2013, be submitted not 
later than 60 days after the publication of the 
notice under paragraph (1); and 
‘‘(B) for each subsequent fiscal year, be 
submitted, updated, or reconfirmed on or before 
June 1 of the previous year. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00066
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(3) CONTENTS OF NOTICE.—At a minimum, 
the submission required by paragraph (2) shall in-
clude for each such facility— 
‘‘(A) identification of a facility identified or 
intended to be identified in an approved or 
pending generic drug submission; 
‘‘(B) whether the facility manufactures ac-
tive pharmaceutical ingredients or finished dos-
age forms, or both; 
‘‘(C) whether or not the facility is located 
within the United States and its territories and 
possessions; 
‘‘(D) whether the facility manufactures 
positron emission tomography drugs solely, or 
in addition to other drugs; and 
‘‘(E) whether the facility manufactures 
drugs that are not generic drugs. 
‘‘(4) CERTAIN SITES AND ORGANIZATIONS.— 
‘‘(A) IN GENERAL.—Any person that owns 
or operates a site or organization described in 
subparagraph (B) shall submit to the Secretary 
information concerning the ownership, name, 
and address of the site or organization. 
‘‘(B) SITES AND ORGANIZATIONS.—A site 
or organization is described in this subpara-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00067
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
graph if it is identified in a generic drug sub-
mission and is— 
‘‘(i) a site in which a bioanalytical 
study is conducted; 
‘‘(ii) a clinical research organization; 
‘‘(iii) a contract analytical testing site; 
or 
‘‘(iv) a contract repackager site. 
‘‘(C) NOTICE.—The Secretary may, by no-
tice published in the Federal Register, specify 
the means and format for submission of the in-
formation under subparagraph (A) and may 
specify, as necessary for purposes of this sec-
tion, any additional information to be sub-
mitted. 
‘‘(D) INSPECTION AUTHORITY.—The Sec-
retary’s inspection authority under section 
704(a)(1) shall extend to all such sites and or-
ganizations. 
‘‘(g) EFFECT OF FAILURE TO PAY FEES.— 
‘‘(1) GENERIC DRUG BACKLOG FEE.—Failure 
to pay the fee under subsection (a)(1) shall result in 
the Secretary placing the person that owns the ab-
breviated new drug application subject to that fee on 
an arrears list, such that no new abbreviated new 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00068
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
drug applications or supplement submitted on or 
after October 1, 2012, from that person, or any af-
filiate of that person, will be received within the 
meaning of section 505(j)(5)(A) until such out-
standing fee is paid. 
‘‘(2) DRUG MASTER FILE FEE.— 
‘‘(A) Failure to pay the fee under sub-
section (a)(2) within 20 calendar days after the 
applicable due date under subparagraph (E) of 
such subsection (as described in subsection 
(a)(2)(D)(ii)(I)) shall result in the Type II ac-
tive pharmaceutical ingredient drug master file 
not being deemed available for reference. 
‘‘(B)(i) Any generic drug submission sub-
mitted on or after October 1, 2012, that ref-
erences, by a letter of authorization, a Type II 
active pharmaceutical ingredient drug master 
file that has not been deemed available for ref-
erence shall not be received within the meaning 
of section 505(j)(5)(A) unless the condition 
specified in clause (ii) is met. 
‘‘(ii) The condition specified in this clause 
is that the fee established under subsection 
(a)(2) has been paid within 20 calendar days of 
the Secretary providing the notification to the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00069
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
sponsor of the abbreviated new drug application 
or supplement of the failure of the owner of the 
Type II active pharmaceutical ingredient drug 
master file to pay the drug master file fee as 
specified in subparagraph (C). 
‘‘(C)(i) If an abbreviated new drug applica-
tion or supplement to an abbreviated new drug 
application references a Type II active pharma-
ceutical ingredient drug master file for which a 
fee under subsection (a)(2)(A) has not been 
paid by the applicable date under subsection 
(a)(2)(E), the Secretary shall notify the sponsor 
of the abbreviated new drug application or sup-
plement of the failure of the owner of the Type 
II active pharmaceutical ingredient drug master 
file to pay the applicable fee. 
‘‘(ii) If such fee is not paid within 20 cal-
endar days of the Secretary providing the noti-
fication, the abbreviated new drug application 
or supplement to an abbreviated new drug ap-
plication shall not be received within the mean-
ing of 505(j)(5)(A). 
‘‘(3) ABBREVIATED
NEW
DRUG
APPLICATION 
FEE
AND
PRIOR
APPROVAL
SUPPLEMENT
FEE.— 
Failure to pay a fee under subparagraph (A) or (F) 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00070
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
of subsection (a)(3) within 20 calendar days of the 
applicable due date under subparagraph (C) of such 
subsection shall result in the abbreviated new drug 
application or the prior approval supplement to an 
abbreviated new drug application not being received 
within the meaning of section 505(j)(5)(A) until 
such outstanding fee is paid. 
‘‘(4) GENERIC DRUG FACILITY FEE AND ACTIVE 
PHARMACEUTICAL INGREDIENT FACILITY FEE.— 
‘‘(A) IN GENERAL.—Failure to pay the fee 
under subsection (a)(4) within 20 calendar days 
of the due date as specified in subparagraph 
(D) of such subsection shall result in the fol-
lowing: 
‘‘(i) The Secretary shall place the fa-
cility on a publicly available arrears list, 
such that no new abbreviated new drug ap-
plication or supplement submitted on or 
after October 1, 2012, from the person 
that is responsible for paying such fee, or 
any affiliate of that person, will be received 
within the meaning of section 505(j)(5)(A). 
‘‘(ii) Any new generic drug submission 
submitted on or after October 1, 2012, 
that references such a facility shall not be 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00071
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
received, within the meaning of section 
505(j)(5)(A) if the outstanding facility fee 
is not paid within 20 calendar days of the 
Secretary providing the notification to the 
sponsor of the failure of the owner of the 
facility to pay the facility fee under sub-
section (a)(4)(C). 
‘‘(iii) All drugs or active pharma-
ceutical ingredients manufactured in such 
a facility or containing an ingredient man-
ufactured in such a facility shall be deemed 
misbranded under section 502(aa). 
‘‘(B) APPLICATION
OF
PENALTIES.—The 
penalties under this paragraph shall apply until 
the fee established by subsection (a)(4) is paid 
or the facility is removed from all generic drug 
submissions that refer to the facility. 
‘‘(C) NONRECEIVAL FOR NONPAYMENT.— 
‘‘(i) NOTICE.—If an abbreviated new 
drug application or supplement to an ab-
breviated new drug application submitted 
on or after October 1, 2012, references a 
facility for which a facility fee has not been 
paid by the applicable date under sub-
section (a)(4)(C), the Secretary shall notify 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00072
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
the sponsor of the generic drug submission 
of the failure of the owner of the facility 
to pay the facility fee. 
‘‘(ii) NONRECEIVAL.—If the facility 
fee is not paid within 20 calendar days of 
the Secretary providing the notification 
under clause (i), the abbreviated new drug 
application or supplement to an abbre-
viated new drug application shall not be re-
ceived within the meaning of section 
505(j)(5)(A). 
‘‘(h) LIMITATIONS.— 
‘‘(1) IN GENERAL.—Fees under subsection (a) 
shall be refunded for a fiscal year beginning after 
fiscal year 2012, unless appropriations for salaries 
and expenses of the Food and Drug Administration 
for such fiscal year (excluding the amount of fees 
appropriated for such fiscal year) are equal to or 
greater than the amount of appropriations for the 
salaries and expenses of the Food and Drug Admin-
istration for the fiscal year 2009 (excluding the 
amount of fees appropriated for such fiscal year) 
multiplied by the adjustment factor (as defined in 
section 744A) applicable to the fiscal year involved. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00073
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(2) AUTHORITY.—If the Secretary does not 
assess fees under subsection (a) during any portion 
of a fiscal year and if at a later date in such fiscal 
year the Secretary may assess such fees, the Sec-
retary may assess and collect such fees, without any 
modification in the rate, for Type II active pharma-
ceutical ingredient drug master files, abbreviated 
new drug applications and prior approval supple-
ments, and generic drug facilities and active phar-
maceutical ingredient facilities at any time in such 
fiscal year notwithstanding the provisions of sub-
section (a) relating to the date fees are to be paid. 
‘‘(i) CREDITING AND AVAILABILITY OF FEES.— 
‘‘(1) IN GENERAL.—Fees authorized under sub-
section (a) shall be collected and available for obliga-
tion only to the extent and in the amount provided 
in advance in appropriations Acts, subject to para-
graph (2). Such fees are authorized to remain avail-
able until expended. Such sums as may be necessary 
may be transferred from the Food and Drug Admin-
istration salaries and expenses appropriation account 
without fiscal year limitation to such appropriation 
account for salaries and expenses with such fiscal 
year limitation. The sums transferred shall be avail-
able solely for human generic drug activities. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00074
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(2) 
COLLECTIONS
AND
APPROPRIATION 
ACTS.— 
‘‘(A) IN
GENERAL.—The fees authorized 
by this section— 
‘‘(i) subject to subparagraphs (C) and 
(D), shall be collected and available in each 
fiscal year in an amount not to exceed the 
amount specified in appropriation Acts, or 
otherwise made available for obligation for 
such fiscal year; and 
‘‘(ii) shall be available for a fiscal year 
beginning after fiscal year 2012 to defray 
the costs of human generic drug activities 
(including such costs for an additional 
number of full-time equivalent positions in 
the Department of Health and Human 
Services to be engaged in such activities), 
only if the Secretary allocates for such 
purpose an amount for such fiscal year 
(excluding amounts from fees collected 
under 
this 
section) 
no 
less 
than 
$97,000,000 multiplied by the adjustment 
factor defined in section 744A(3) applica-
ble to the fiscal year involved. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00075
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) COMPLIANCE.—The Secretary shall 
be considered to have met the requirements of 
subparagraph (A)(ii) in any fiscal year if the 
costs funded by appropriations and allocated for 
human generic activities are not more than 10 
percent below the level specified in such sub-
paragraph. 
‘‘(C) FEE
COLLECTION
DURING
FIRST 
PROGRAM YEAR.—Until the date of enactment 
of an Act making appropriations through Sep-
tember 30, 2013 for the salaries and expenses 
account of the Food and Drug Administration, 
fees authorized by this section for fiscal year 
2013, may be collected and shall be credited to 
such account and remain available until ex-
pended. 
‘‘(D) PROVISION FOR EARLY PAYMENTS IN 
SUBSEQUENT YEARS.—Payment of fees author-
ized under this section for a fiscal year (after 
fiscal year 2013), prior to the due date for such 
fees, may be accepted by the Secretary in ac-
cordance with authority provided in advance in 
a prior year appropriations Act. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of the fiscal years 2013 through 2017, 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
there is authorized to be appropriated for fees under 
this section an amount equivalent to the total rev-
enue amount determined under subsection (b) for 
the fiscal year, as adjusted under subsection (c), if 
applicable, or as otherwise affected under paragraph 
(2) of this subsection. 
‘‘(j) COLLECTION OF UNPAID FEES.—In any case 
where the Secretary does not receive payment of a fee as-
sessed under subsection (a) within 30 calendar days after 
it is due, such fee shall be treated as a claim of the United 
States Government subject to subchapter II of chapter 37 
of title 31, United States Code. 
‘‘(k) CONSTRUCTION.—This section may not be con-
strued to require that the number of full-time equivalent 
positions in the Department of Health and Human Serv-
ices, for officers, employees, and advisory committees not 
engaged in human generic drug activities, be reduced to 
offset the number of officers, employees, and advisory 
committees so engaged. 
‘‘(l) POSITRON EMISSION TOMOGRAPHY DRUGS.— 
‘‘(1) EXEMPTION FROM FEES.—Submission of 
an application for a positron emission tomography 
drug or active pharmaceutical ingredient for a 
positron emission tomography drug shall not require 
the payment of any fee under this section. Facilities 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
that solely produce positron emission tomography 
drugs shall not be required to pay a facility fee as 
established in subsection (a)(4). 
‘‘(2) IDENTIFICATION
REQUIREMENT.—Facili-
ties that produce positron emission tomography 
drugs or active pharmaceutical ingredients of such 
drugs are required to be identified pursuant to sub-
section (f). 
‘‘(m) DISPUTES CONCERNING FEES.—To qualify for 
the return of a fee claimed to have been paid in error 
under this section, a person shall submit to the Secretary 
a written request justifying such return within 180 cal-
endar days after such fee was paid. 
‘‘(n) SUBSTANTIALLY COMPLETE APPLICATIONS.— 
An abbreviated new drug application that is not consid-
ered to be received within the meaning of section 
505(j)(5)(A) because of failure to pay an applicable fee 
under this provision within the time period specified in 
subsection (g) shall be deemed not to have been ‘substan-
tially complete’ on the date of its submission within the 
meaning of section 505(j)(5)(B)(iv)(II)(cc). An abbre-
viated new drug application that is not substantially com-
plete on the date of its submission solely because of failure 
to pay an applicable fee under the preceding sentence shall 
be deemed substantially complete and received within the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00078
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
meaning of section 505(j)(5)(A) as of the date such appli-
cable fee is received.’’. 
SEC. 303. REAUTHORIZATION; REPORTING REQUIREMENTS. 
Part 7 of subchapter C of chapter VII, as added by 
section 302 of this Act, is amended by inserting after sec-
tion 744B the following: 
‘‘SEC. 744C. REAUTHORIZATION; REPORTING REQUIRE-
MENTS. 
‘‘(a) PERFORMANCE REPORT.— 
‘‘(1) IN GENERAL.—Beginning with fiscal year 
2013, not later than 120 days after the end of each 
fiscal year for which fees are collected under this 
part, the Secretary shall prepare and submit to the 
Committee on Energy and Commerce of the House 
of Representatives and the Committee on Health, 
Education, Labor, and Pensions of the Senate a re-
port concerning the progress of the Food and Drug 
Administration in achieving the goals identified in 
the letters described in section 301(b) of the Generic 
Drug User Fee Amendments of 2012 during such 
fiscal year and the future plans of the Food and 
Drug Administration for meeting the goals. 
‘‘(2) REGULATORY
SCIENCE
ACCOUNTABILITY 
METRICS.—The report required by paragraph (1) 
shall describe the amounts spent, data generated, 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00079
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
and activities undertaken, including any FDA Advi-
sory Committee consideration, by the Secretary for 
each of the local acting bioequivalence topics (Topics 
1–3) in the Regulatory Science Plan described in the 
letters described in section 301(b) of the Generic 
Drug User Fee Amendments of 2012. 
‘‘(b) FISCAL REPORT.—Beginning with fiscal year 
2013, not later than 120 days after the end of each fiscal 
year for which fees are collected under this part, the Sec-
retary shall prepare and submit to the Committee on En-
ergy and Commerce of the House of Representatives and 
the Committee on Health, Education, Labor, and Pen-
sions of the Senate a report on the implementation of the 
authority for such fees during such fiscal year and the 
use, by the Food and Drug Administration, of the fees 
collected for such fiscal year. 
‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 
make the reports required under subsections (a) and (b) 
available to the public on the Internet Web site of the 
Food and Drug Administration. 
‘‘(d) REAUTHORIZATION.— 
‘‘(1) 
CONSULTATION.—In 
developing 
rec-
ommendations to present to the Congress with re-
spect to the goals, and plans for meeting the goals, 
for human generic drug activities for the first 5 fis-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00080
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
cal years after fiscal year 2017, and for the reau-
thorization of this part for such fiscal years, the Sec-
retary shall consult with— 
‘‘(A) the Committee on Energy and Com-
merce of the House of Representatives; 
‘‘(B) the Committee on Health, Education, 
Labor, and Pensions of the Senate; 
‘‘(C) scientific and academic experts; 
‘‘(D) health care professionals; 
‘‘(E) representatives of patient and con-
sumer advocacy groups; and 
‘‘(F) the generic drug industry. 
‘‘(2) PRIOR PUBLIC INPUT.—Prior to beginning 
negotiations with the generic drug industry on the 
reauthorization of this part, the Secretary shall— 
‘‘(A) publish a notice in the Federal Reg-
ister requesting public input on the reauthoriza-
tion; 
‘‘(B) hold a public meeting at which the 
public may present its views on the reauthoriza-
tion, including specific suggestions for changes 
to the goals referred to in subsection (a); 
‘‘(C) provide a period of 30 days after the 
public meeting to obtain written comments from 
the public suggesting changes to this part; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00081
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(D) publish the comments on the Food 
and Drug Administration’s Internet Web site. 
‘‘(3) PERIODIC CONSULTATION.—Not less fre-
quently than once every month during negotiations 
with the generic drug industry, the Secretary shall 
hold discussions with representatives of patient and 
consumer advocacy groups to continue discussions of 
their views on the reauthorization and their sugges-
tions for changes to this part as expressed under 
paragraph (2). 
‘‘(4) 
PUBLIC
REVIEW
OF
RECOMMENDA-
TIONS.—After negotiations with the generic drug in-
dustry, the Secretary shall— 
‘‘(A) present the recommendations devel-
oped under paragraph (1) to the congressional 
committees specified in such paragraph; 
‘‘(B) publish such recommendations in the 
Federal Register; 
‘‘(C) provide for a period of 30 days for 
the public to provide written comments on such 
recommendations; 
‘‘(D) hold a meeting at which the public 
may present its views on such recommenda-
tions; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00082
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(E) after consideration of such public 
views and comments, revise such recommenda-
tions as necessary. 
‘‘(5) TRANSMITTAL OF RECOMMENDATIONS.— 
Not later than January 15, 2017, the Secretary 
shall transmit to the Congress the revised rec-
ommendations under paragraph (4), a summary of 
the views and comments received under such para-
graph, and any changes made to the recommenda-
tions in response to such views and comments. 
‘‘(6) MINUTES OF NEGOTIATION MEETINGS.— 
‘‘(A) PUBLIC AVAILABILITY.—Before pre-
senting the recommendations developed under 
paragraphs (1) through (5) to the Congress, the 
Secretary shall make publicly available, on the 
Internet Web site of the Food and Drug Ad-
ministration, minutes of all negotiation meet-
ings conducted under this subsection between 
the Food and Drug Administration and the ge-
neric drug industry. 
‘‘(B) CONTENT.—The minutes described 
under subparagraph (A) shall summarize any 
substantive proposal made by any party to the 
negotiations as well as significant controversies 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00083
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
or differences of opinion during the negotiations 
and their resolution.’’. 
SEC. 304. SUNSET DATES. 
(a) AUTHORIZATION.—Sections 744A and 744B, as 
added by section 302 of this Act, are repealed October 
1, 2017. 
(b) REPORTING REQUIREMENTS.—Section 744C, as 
added by section 303 of this Act, is repealed January 31, 
2018. 
SEC. 305. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2012, or the date of the enactment of this 
title, whichever is later, except that fees under section 302 
shall be assessed for all human generic drug submissions 
and Type II active pharmaceutical drug master files re-
ceived on or after October 1, 2012, regardless of the date 
of enactment of this title. 
SEC. 306. AMENDMENT WITH RESPECT TO MISBRANDING. 
Section 502 (21 U.S.C. 352) is amended by adding 
at the end the following: 
‘‘(aa) If it is a drug, or an active pharmaceutical in-
gredient, and it was manufactured, prepared, propagated, 
compounded, or processed in a facility for which fees have 
not been paid as required by section 744A(a)(4) or for 
which identifying information required by section 744B(f) 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00084
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
has not been submitted, or it contains an active pharma-
ceutical ingredient that was manufactured, prepared, 
propagated, compounded, or processed in such a facility.’’. 
SEC. 307. STREAMLINED HIRING AUTHORITY TO SUPPORT 
ACTIVITIES RELATED TO HUMAN GENERIC 
DRUGS. 
Section 714, as added by section 208 of this Act, is 
amended— 
(1) by amending subsection (b) to read as fol-
lows: 
‘‘(b) ACTIVITIES DESCRIBED.—The activities de-
scribed in this subsection are— 
‘‘(1) activities under this Act related to the 
process for the review of device applications (as de-
fined in section 737(8)); and 
‘‘(2) activities under this Act related to human 
generic drug activities (as defined in section 
744A).’’; and 
(2) by amending subsection (c) to read as fol-
lows: 
‘‘(c) OBJECTIVES SPECIFIED.—The objectives speci-
fied in this subsection are— 
‘‘(1) with respect to the activities under sub-
section (b)(1), the goals referred to in section 
738A(a)(1); and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00085
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(2) with respect to the activities under sub-
section (b)(2), the goals referred to in section 
744C(a).’’. 
TITLE IV—FEES RELATING TO 
BIOSIMILAR 
BIOLOGICAL 
PRODUCTS 
SEC. 401. SHORT TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Biosimilar User Fee Act of 2012’’. 
(b) FINDING.—The Congress finds that the fees au-
thorized by the amendments made in this title will be dedi-
cated to expediting the process for the review of biosimilar 
biological product applications, including postmarket safe-
ty activities, as set forth in the goals identified for pur-
poses of part 8 of subchapter C of chapter VII of the Fed-
eral Food, Drug, and Cosmetic Act, in the letters from 
the Secretary of Health and Human Services to the Chair-
man of the Committee on Health, Education, Labor, and 
Pensions of the Senate and the Chairman of the Com-
mittee on Energy and Commerce of the House of Rep-
resentatives, as set forth in the Congressional Record. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00086
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
SEC. 402. FEES RELATING TO BIOSIMILAR BIOLOGICAL 
PRODUCTS. 
Subchapter C of chapter VII (21 U.S.C. 379f et seq.) 
is amended by inserting after part 7, as added by title 
III of this Act, the following: 
‘‘PART 8—FEES RELATING TO BIOSIMILAR 
BIOLOGICAL PRODUCTS 
‘‘SEC. 744G. DEFINITIONS. 
‘‘For purposes of this part: 
‘‘(1) The term ‘adjustment factor’ applicable to 
a fiscal year that is the Consumer Price Index for 
all urban consumers (Washington-Baltimore, DC– 
MD–VA–WV; Not Seasonally Adjusted; All items) of 
the preceding fiscal year divided by such Index for 
September 2011. 
‘‘(2) The term ‘affiliate’ means a business enti-
ty that has a relationship with a second business en-
tity if, directly or indirectly— 
‘‘(A) one business entity controls, or has 
the power to control, the other business entity; 
or 
‘‘(B) a third party controls, or has power 
to control, both of the business entities. 
‘‘(3) The term ‘biosimilar biological product’ 
means a product for which a biosimilar biological 
product application has been approved. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00087
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(4)(A) Subject to subparagraph (B), the term 
‘biosimilar biological product application’ means an 
application for licensure of a biological product 
under section 351(k) of the Public Health Service 
Act. 
‘‘(B) Such term does not include— 
‘‘(i) a supplement to such an application; 
‘‘(ii) an application filed under section 
351(k) of the Public Health Service Act that 
cites as the reference product a bovine blood 
product for topical application licensed before 
September 1, 1992, or a large volume paren-
teral drug product approved before such date; 
‘‘(iii) an application filed under section 
351(k) of the Public Health Service Act with 
respect to— 
‘‘(I) whole blood or a blood component 
for transfusion; 
‘‘(II) an allergenic extract product; 
‘‘(III) an in vitro diagnostic biological 
product; or 
‘‘(IV) a biological product for further 
manufacturing use only; or 
‘‘(iv) an application for licensure under 
section 351(k) of the Public Health Service Act 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00088
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
that is submitted by a State or Federal Govern-
ment entity for a product that is not distributed 
commercially. 
‘‘(5) The term ‘biosimilar biological product de-
velopment meeting’ means any meeting, other than 
a biosimilar initial advisory meeting, regarding the 
content of a development program, including a pro-
posed design for, or data from, a study intended to 
support a biosimilar biological product application. 
‘‘(6) The term ‘biosimilar biological product de-
velopment program’ means the program under this 
part for expediting the process for the review of sub-
missions in connection with biosimilar biological 
product development. 
‘‘(7)(A) The term ‘biosimilar biological product 
establishment’ means a foreign or domestic place of 
business— 
‘‘(i) that is at one general physical location 
consisting of one or more buildings, all of which 
are within five miles of each other; and 
‘‘(ii) at which one or more biosimilar bio-
logical products are manufactured in final dos-
age form. 
‘‘(B) For purposes of subparagraph (A)(ii), the 
term ‘manufactured’ does not include packaging. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00089
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(8) The term ‘biosimilar initial advisory meet-
ing’— 
‘‘(A) means a meeting, if requested, that is 
limited to— 
‘‘(i) a general discussion regarding 
whether licensure under section 351(k) of 
the Public Health Service Act may be fea-
sible for a particular product; and 
‘‘(ii) if so, general advice on the ex-
pected content of the development pro-
gram; and 
‘‘(B) does not include any meeting that in-
volves substantive review of summary data or 
full study reports. 
‘‘(9) The term ‘costs of resources allocated for 
the process for the review of biosimilar biological 
product applications’ means the expenses in connec-
tion with the process for the review of biosimilar bio-
logical product applications for— 
‘‘(A) officers and employees of the Food 
and Drug Administration, contractors of the 
Food and Drug Administration, advisory com-
mittees, and costs related to such officers em-
ployees and committees and to contracts with 
such contractors; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00090
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) management of information, and the 
acquisition, maintenance, and repair of com-
puter resources; 
‘‘(C) leasing, maintenance, renovation, and 
repair of facilities and acquisition, maintenance, 
and repair of fixtures, furniture, scientific 
equipment, and other necessary materials and 
supplies; and 
‘‘(D) collecting fees under section 744H 
and accounting for resources allocated for the 
review of submissions in connection with bio-
similar biological product development, bio-
similar biological product applications, and sup-
plements. 
‘‘(10) The term ‘final dosage form’ means, with 
respect to a biosimilar biological product, a finished 
dosage form which is approved for administration to 
a patient without substantial further manufacturing 
(such as lyophilized products before reconstitution). 
‘‘(11) The term ‘financial hold’— 
‘‘(A) means an order issued by the Sec-
retary to prohibit the sponsor of a clinical in-
vestigation from continuing the investigation if 
the Secretary determines that the investigation 
is intended to support a biosimilar biological 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00091
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
product application and the sponsor has failed 
to pay any fee for the product required under 
subparagraph (A), (B), or (D) of section 
744H(a)(1); and 
‘‘(B) does not mean that any of the bases 
for a ‘clinical hold’ under section 505(i)(3) have 
been determined by the Secretary to exist con-
cerning the investigation. 
‘‘(12) The term ‘person’ includes an affiliate of 
such person. 
‘‘(13) The term ‘process for the review of bio-
similar biological product applications’ means the 
following activities of the Secretary with respect to 
the review of submissions in connection with bio-
similar biological product development, biosimilar bi-
ological product applications, and supplements: 
‘‘(A) The activities necessary for the re-
view of submissions in connection with bio-
similar biological product development, bio-
similar biological product applications, and sup-
plements. 
‘‘(B) Actions related to submissions in con-
nection with biosimilar biological product devel-
opment, the issuance of action letters which ap-
prove biosimilar biological product applications 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00092
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
or which set forth in detail the specific defi-
ciencies in such applications, and where appro-
priate, the actions necessary to place such ap-
plications in condition for approval. 
‘‘(C) The inspection of biosimilar biological 
product establishments and other facilities un-
dertaken as part of the Secretary’s review of 
pending biosimilar biological product applica-
tions and supplements. 
‘‘(D) Activities necessary for the release of 
lots of biosimilar biological products under sec-
tion 351(k) of the Public Health Service Act. 
‘‘(E) Monitoring of research conducted in 
connection with the review of biosimilar biologi-
cal product applications. 
‘‘(F) Postmarket safety activities with re-
spect to biologics approved under biosimilar bio-
logical product applications or supplements, in-
cluding the following activities: 
‘‘(i) Collecting, developing, and re-
viewing safety information on biosimilar bi-
ological products, including adverse-event 
reports. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00093
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(ii) Developing and using improved 
adverse-event data-collection systems, in-
cluding information technology systems. 
‘‘(iii) Developing and using improved 
analytical tools to assess potential safety 
problems, including access to external data 
bases. 
‘‘(iv) Implementing and enforcing sec-
tion 505(o) (relating to postapproval stud-
ies and clinical trials and labeling changes) 
and section 505(p) (relating to risk evalua-
tion and mitigation strategies). 
‘‘(v) Carrying out section 505(k)(5) 
(relating to adverse-event reports and 
postmarket safety activities). 
‘‘(14) The term ‘supplement’ means a request 
to the Secretary to approve a change in a biosimilar 
biological product application which has been ap-
proved, including a supplement requesting that the 
Secretary determine that the biosimilar biological 
product meets the standards for interchangeability 
described in section 351(k)(4) of the Public Health 
Service Act. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00094
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
‘‘SEC. 744H. AUTHORITY TO ASSESS AND USE BIOSIMILAR 
BIOLOGICAL PRODUCT FEES. 
‘‘(a) TYPES
OF FEES.—Beginning in fiscal year 
2013, the Secretary shall assess and collect fees in accord-
ance with this section as follows: 
‘‘(1) 
BIOSIMILAR
DEVELOPMENT
PROGRAM 
FEES.— 
‘‘(A) 
INITIAL
BIOSIMILAR
BIOLOGICAL 
PRODUCT DEVELOPMENT FEE.— 
‘‘(i) IN GENERAL.—Each person that 
submits to the Secretary a meeting request 
described under clause (ii) or a clinical 
protocol for an investigational new drug 
protocol described under clause (iii) shall 
pay for the product named in the meeting 
request or the investigational new drug ap-
plication the initial biosimilar biological 
product development fee established under 
subsection (b)(1)(A). 
‘‘(ii) MEETING REQUEST.—The meet-
ing request defined in this clause is a re-
quest for a biosimilar biological product 
development meeting for a product. 
‘‘(iii) CLINICAL PROTOCOL FOR IND.— 
A clinical protocol for an investigational 
new drug protocol described in this clause 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00095
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
is a clinical protocol consistent with the 
provisions of section 505(i), including any 
regulations promulgated under section 
505(i), (referred to in this section as ‘in-
vestigational new drug application’) de-
scribing an investigation that the Secretary 
determines is intended to support a bio-
similar biological product application for a 
product. 
‘‘(iv) DUE
DATE.—The initial bio-
similar biological product development fee 
shall be due by the earlier of the following: 
‘‘(I) Not later than 5 days after 
the Secretary grants a request for a 
biosimilar biological product develop-
ment meeting. 
‘‘(II) The date of submission of 
an investigational new drug applica-
tion describing an investigation that 
the Secretary determines is intended 
to support a biosimilar biological 
product application. 
‘‘(v) TRANSITION
RULE.—Each per-
son that has submitted an investigational 
new drug application prior to the date of 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00096
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
enactment of the Biosimilars User Fee Act 
of 2012 shall pay the initial biosimilar bio-
logical product development fee by the ear-
lier of the following: 
‘‘(I) Not later than 60 days after 
the date of the enactment of the 
Biosimilars User Fee Act of 2012, if 
the Secretary determines that the in-
vestigational new drug application de-
scribes an investigation that is in-
tended to support a biosimilar biologi-
cal product application. 
‘‘(II) Not later than 5 days after 
the Secretary grants a request for a 
biosimilar biological product develop-
ment meeting. 
‘‘(B) ANNUAL
BIOSIMILAR
BIOLOGICAL 
PRODUCT DEVELOPMENT FEE.— 
‘‘(i) IN
GENERAL.—A person that 
pays an initial biosimilar biological product 
development fee for a product shall pay for 
such product, beginning in the fiscal year 
following the fiscal year in which the initial 
biosimilar biological product development 
fee was paid, an annual fee established 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00097
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
under subsection (b)(1)(B) for biosimilar 
biological product development (referred to 
in this section as ‘annual biosimilar bio-
logical product development fee’). 
‘‘(ii) DUE
DATE.—The annual bio-
similar biological product development pro-
gram fee for each fiscal year will be due on 
the later of— 
‘‘(I) the first business day on or 
after October 1 of each such year; or 
‘‘(II) the first business day after 
the enactment of an appropriations 
Act providing for the collection and 
obligation of fees for such year under 
this section. 
‘‘(iii) EXCEPTION.—The annual bio-
similar development program fee for each 
fiscal year will be due on the date specified 
in clause (ii), unless the person has— 
‘‘(I) submitted a marketing appli-
cation for the biological product that 
was accepted for filing; or 
‘‘(II) discontinued participation 
in the biosimilar biological product de-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00098
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
velopment program for the product 
under subparagraph (C). 
‘‘(C) DISCONTINUATION OF FEE OBLIGA-
TION.—A person may discontinue participation 
in the biosimilar biological product development 
program for a product effective October 1 of a 
fiscal year by, not later than August 1 of the 
preceding fiscal year— 
‘‘(i) if no investigational new drug ap-
plication concerning the product has been 
submitted, submitting to the Secretary a 
written declaration that the person has no 
present intention of further developing the 
product as a biosimilar biological product; 
or 
‘‘(ii) if an investigational new drug 
application concerning the product has 
been submitted, by withdrawing the inves-
tigational new drug application in accord-
ance with part 312 of title 21, Code of 
Federal Regulations (or any successor reg-
ulations). 
‘‘(D) REACTIVATION FEE.— 
‘‘(i) IN GENERAL.—A person that has 
discontinued participation in the biosimilar 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00099
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
100 
biological product development program for 
a product under subparagraph (C) shall 
pay a fee (referred to in this section as ‘re-
activation fee’) by the earlier of the fol-
lowing: 
‘‘(I) Not later than 5 days after 
the Secretary grants a request for a 
biosimilar biological product develop-
ment meeting for the product (after 
the date on which such participation 
was discontinued). 
‘‘(II) Upon the date of submis-
sion (after the date on which such 
participation was discontinued) of an 
investigational new drug application 
describing an investigation that the 
Secretary determines is intended to 
support a biosimilar biological product 
application for that product. 
‘‘(ii) 
APPLICATION
OF
ANNUAL 
FEE.—A person that pays a reactivation 
fee for a product shall pay for such prod-
uct, beginning in the next fiscal year, the 
annual biosimilar biological product devel-
opment fee under subparagraph (B). 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00100
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
101 
‘‘(E) EFFECT OF FAILURE TO PAY BIO-
SIMILAR DEVELOPMENT PROGRAM FEES.— 
‘‘(i) 
NO
BIOSIMILAR
BIOLOGICAL 
PRODUCT DEVELOPMENT MEETINGS.—If a 
person has failed to pay an initial or an-
nual biosimilar biological product develop-
ment fee as required under subparagraph 
(A) or (B), or a reactivation fee as re-
quired under subparagraph (D), the Sec-
retary shall not provide a biosimilar bio-
logical product development meeting relat-
ing to the product for which fees are owed. 
‘‘(ii) NO
RECEIPT
OF
INVESTIGA-
TIONAL
NEW
DRUG
APPLICATIONS.—Ex-
cept in extraordinary circumstances, the 
Secretary shall not consider an investiga-
tional new drug application to have been 
received under section 505(i)(2) if— 
‘‘(I) the Secretary determines 
that the investigation is intended to 
support a biosimilar biological product 
application; and 
‘‘(II) the sponsor has failed to 
pay an initial or annual biosimilar bio-
logical product development fee for 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00101
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
102 
the product as required under sub-
paragraph (A) or (B), or a reactiva-
tion fee as required under subpara-
graph (D). 
‘‘(iii) 
FINANCIAL
HOLD.—Notwith-
standing section 505(i)(2), except in ex-
traordinary circumstances, the Secretary 
shall prohibit the sponsor of a clinical in-
vestigation from continuing the investiga-
tion if— 
‘‘(I) the Secretary determines 
that the investigation is intended to 
support a biosimilar biological product 
application; and 
‘‘(II) the sponsor has failed to 
pay an initial or annual biosimilar bio-
logical product development fee for 
the product as required under sub-
paragraph (A) or (B), or a reactiva-
tion fee for the product as required 
under subparagraph (D). 
‘‘(iv) NO ACCEPTANCE OF BIOSIMILAR 
BIOLOGICAL
PRODUCT
APPLICATIONS
OR 
SUPPLEMENTS.—If a person has failed to 
pay an initial or annual biosimilar biologi-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00102
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
103 
cal product development fee as required 
under subparagraph (A) or (B), or a reac-
tivation fee as required under subpara-
graph (D), any biosimilar biological prod-
uct application or supplement submitted by 
that person shall be considered incomplete 
and shall not be accepted for filing by the 
Secretary until all such fees owed by such 
person have been paid. 
‘‘(F) LIMITS REGARDING BIOSIMILAR DE-
VELOPMENT PROGRAM FEES.— 
‘‘(i) NO
REFUNDS.—The Secretary 
shall not refund any initial or annual bio-
similar biological product development fee 
paid under subparagraph (A) or (B), or 
any reactivation fee paid under subpara-
graph (D). 
‘‘(ii) NO WAIVERS, EXEMPTIONS, OR 
REDUCTIONS.—The Secretary shall not 
grant a waiver, exemption, or reduction of 
any initial or annual biosimilar biological 
product development fee due or payable 
under subparagraph (A) or (B), or any re-
activation fee due or payable under sub-
paragraph (D). 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00103
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
104 
‘‘(2) BIOSIMILAR BIOLOGICAL PRODUCT APPLI-
CATION AND SUPPLEMENT FEE.— 
‘‘(A) IN GENERAL.—Each person that sub-
mits, on or after October 1, 2012, a biosimilar 
biological product application or a supplement 
shall be subject to the following fees: 
‘‘(i) A fee for a biosimilar biological 
product application that is equal to— 
‘‘(I) the amount of the fee estab-
lished under subsection (b)(1)(D) for 
a biosimilar biological product applica-
tion; minus 
‘‘(II) the cumulative amount of 
fees paid, if any, under subparagraphs 
(A), (B), and (D) of paragraph (1) 
for the product that is the subject of 
the application. 
‘‘(ii) A fee for a biosimilar biological 
product application for which clinical data 
(other than comparative bioavailability 
studies) with respect to safety or effective-
ness are not required, that is equal to— 
‘‘(I) half of the amount of the fee 
established under subsection (b)(1)(D) 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00104
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
105 
for a biosimilar biological product ap-
plication; minus 
‘‘(II) the cumulative amount of 
fees paid, if any, under subparagraphs 
(A), (B), and (D) of paragraph (1) 
for that product. 
‘‘(iii) A fee for a supplement for which 
clinical data (other than comparative bio-
availability studies) with respect to safety 
or effectiveness are required, that is equal 
to half of the amount of the fee established 
under subsection (b)(1)(D) for a biosimilar 
biological product application. 
‘‘(B) 
REDUCTION
IN
FEES.—Notwith-
standing section 404 of the Biosimilars User 
Fee Act of 2012, any person who pays a fee 
under subparagraph (A), (B), or (D) of para-
graph (1) for a product before October 1, 2017, 
but submits a biosimilar biological product ap-
plication for that product after such date, shall 
be entitled to the reduction of any biosimilar bi-
ological product application fees that may be 
assessed at the time when such biosimilar bio-
logical product application is submitted, by the 
cumulative amount of fees paid under subpara-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00105
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
106 
graphs (A), (B), and (D) of paragraph (1) for 
that product. 
‘‘(C) PAYMENT DUE DATE.—Any fee re-
quired by subparagraph (A) shall be due upon 
submission of the application or supplement for 
which such fee applies. 
‘‘(D) EXCEPTION FOR PREVIOUSLY FILED 
APPLICATION OR SUPPLEMENT.—If a biosimilar 
biological product application or supplement 
was submitted by a person that paid the fee for 
such application or supplement, was accepted 
for filing, and was not approved or was with-
drawn (without a waiver), the submission of a 
biosimilar biological product application or a 
supplement for the same product by the same 
person (or the person’s licensee, assignee, or 
successor) shall not be subject to a fee under 
subparagraph (A). 
‘‘(E) REFUND OF APPLICATION FEE IF AP-
PLICATION
REFUSED
FOR
FILING
OR
WITH-
DRAWN BEFORE FILING.—The Secretary shall 
refund 75 percent of the fee paid under this 
paragraph for any application or supplement 
which is refused for filing or withdrawn without 
a waiver before filing. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00106
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
107 
‘‘(F) 
FEES
FOR
APPLICATIONS
PRE-
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
BEFORE FILING.—A biosimilar biological prod-
uct application or supplement that was sub-
mitted but was refused for filing, or was with-
drawn before being accepted or refused for fil-
ing, shall be subject to the full fee under sub-
paragraph (A) upon being resubmitted or filed 
over protest, unless the fee is waived under sub-
section (c). 
‘‘(3) BIOSIMILAR BIOLOGICAL PRODUCT ESTAB-
LISHMENT FEE.— 
‘‘(A) IN GENERAL.—Except as provided in 
subparagraph (E), each person that is named 
as the applicant in a biosimilar biological prod-
uct application shall be assessed an annual fee 
established under subsection (b)(1)(E) for each 
biosimilar biological product establishment that 
is listed in the approved biosimilar biological 
product application as an establishment that 
manufactures the biosimilar biological product 
named in such application. 
‘‘(B) ASSESSMENT IN FISCAL YEARS.—The 
establishment fee shall be assessed in each fis-
cal year for which the biosimilar biological prod-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00107
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
108 
uct named in the application is assessed a fee 
under paragraph (4) unless the biosimilar bio-
logical product establishment listed in the appli-
cation does not engage in the manufacture of 
the biosimilar biological product during such 
fiscal year. 
‘‘(C) DUE DATE.—The establishment fee 
for a fiscal year shall be due on the later of— 
‘‘(i) the first business day on or after 
October 1 of such fiscal year; or 
‘‘(ii) the first business day after the 
enactment of an appropriations Act pro-
viding for the collection and obligation of 
fees for such fiscal year under this section. 
‘‘(D) APPLICATION TO ESTABLISHMENT.— 
‘‘(i) Each biosimilar biological product 
establishment shall be assessed only one 
fee per biosimilar biological product estab-
lishment, notwithstanding the number of 
biosimilar biological products manufac-
tured at the establishment, subject to 
clause (ii). 
‘‘(ii) In the event an establishment is 
listed in a biosimilar biological product ap-
plication by more than one applicant, the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00108
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
109 
establishment fee for the fiscal year shall 
be divided equally and assessed among the 
applicants whose biosimilar biological prod-
ucts are manufactured by the establish-
ment during the fiscal year and assessed 
biosimilar biological product fees under 
paragraph (4). 
‘‘(E) EXCEPTION FOR NEW PRODUCTS.— 
If, during the fiscal year, an applicant initiates 
or causes to be initiated the manufacture of a 
biosimilar biological product at an establish-
ment listed in its biosimilar biological product 
application— 
‘‘(i) that did not manufacture the bio-
similar biological product in the previous 
fiscal year; and 
‘‘(ii) for which the full biosimilar bio-
logical product establishment fee has been 
assessed in the fiscal year at a time before 
manufacture of the biosimilar biological 
product was begun, 
the applicant shall not be assessed a share of 
the biosimilar biological product establishment 
fee for the fiscal year in which the manufacture 
of the product began. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00109
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
110 
‘‘(4) BIOSIMILAR BIOLOGICAL PRODUCT FEE.— 
‘‘(A) IN GENERAL.—Each person who is 
named as the applicant in a biosimilar biologi-
cal product application shall pay for each such 
biosimilar biological product the annual fee es-
tablished under subsection (b)(1)(F). 
‘‘(B) DUE DATE.—The biosimilar biologi-
cal product fee for a fiscal year shall be due on 
the later of— 
‘‘(i) the first business day on or after 
October 1 of each such year; or 
‘‘(ii) the first business day after the 
enactment of an appropriations Act pro-
viding for the collection and obligation of 
fees for such year under this section. 
‘‘(C) ONE FEE PER PRODUCT PER YEAR.— 
The biosimilar biological product fee shall be 
paid only once for each product for each fiscal 
year. 
‘‘(b) FEE SETTING AND AMOUNTS.— 
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
the Secretary shall, 60 days before the start of each 
fiscal year that begins after September 30, 2012, es-
tablish, for the next fiscal year, the fees under sub-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00110
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
111 
section (a). Except as provided in subsection (c), 
such fees shall be in the following amounts: 
‘‘(A) 
INITIAL
BIOSIMILAR
BIOLOGICAL 
PRODUCT DEVELOPMENT FEE.—The initial bio-
similar biological product development fee under 
subsection (a)(1)(A) for a fiscal year shall be 
equal to 10 percent of the amount established 
under section 736(c)(4) for a human drug ap-
plication described in section 736(a)(1)(A)(i) 
for that fiscal year. 
‘‘(B) ANNUAL
BIOSIMILAR
BIOLOGICAL 
PRODUCT
DEVELOPMENT
FEE.—The annual 
biosimilar biological product development fee 
under subsection (a)(1)(B) for a fiscal year 
shall be equal to 10 percent of the amount es-
tablished under section 736(c)(4) for a human 
drug 
application 
described 
in 
section 
736(a)(1)(A)(i) for that fiscal year. 
‘‘(C) REACTIVATION
FEE.—The reactiva-
tion fee under subsection (a)(1)(D) for a fiscal 
year shall be equal to 20 percent of the amount 
of the fee established under section 736(c)(4) 
for a human drug application described in sec-
tion 736(a)(1)(A)(i) for that fiscal year. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00111
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
112 
‘‘(D) BIOSIMILAR
BIOLOGICAL
PRODUCT 
APPLICATION
FEE.—The biosimilar biological 
product application fee under subsection (a)(2) 
for a fiscal year shall be equal to the amount 
established under section 736(c)(4) for a 
human drug application described in section 
736(a)(1)(A)(i) for that fiscal year. 
‘‘(E) BIOSIMILAR
BIOLOGICAL
PRODUCT 
ESTABLISHMENT FEE.—The biosimilar biologi-
cal product establishment fee under subsection 
(a)(3) for a fiscal year shall be equal to the 
amount established under section 736(c)(4) for 
a prescription drug establishment for that fiscal 
year. 
‘‘(F) BIOSIMILAR
BIOLOGICAL
PRODUCT 
FEE.—The biosimilar biological product fee 
under subsection (a)(4) for a fiscal year shall be 
equal to the amount established under section 
736(c)(4) for a prescription drug product for 
that fiscal year. 
‘‘(2) LIMIT.—The total amount of fees charged 
for a fiscal year under this section may not exceed 
the total amount for such fiscal year of the costs of 
resources allocated for the process for the review of 
biosimilar biological product applications. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00112
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
113 
‘‘(c) APPLICATION FEE WAIVER FOR SMALL BUSI-
NESS.— 
‘‘(1) WAIVER OF APPLICATION FEE.—The Sec-
retary shall grant to a person who is named in a bio-
similar biological product application a waiver from 
the application fee assessed to that person under 
subsection (a)(2)(A) for the first biosimilar biologi-
cal product application that a small business or its 
affiliate submits to the Secretary for review. After a 
small business or its affiliate is granted such a waiv-
er, the small business or its affiliate shall pay— 
‘‘(A) application fees for all subsequent 
biosimilar biological product applications sub-
mitted to the Secretary for review in the same 
manner as an entity that is not a small busi-
ness; and 
‘‘(B) all supplement fees for all supple-
ments to biosimilar biological product applica-
tions submitted to the Secretary for review in 
the same manner as an entity that is not a 
small business. 
‘‘(2) CONSIDERATIONS.—In determining wheth-
er to grant a waiver of a fee under paragraph (1), 
the Secretary shall consider only the circumstances 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00113
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
114 
and assets of the applicant involved and any affiliate 
of the applicant. 
‘‘(3) SMALL BUSINESS DEFINED.—In this sub-
section, the term ‘small business’ means an entity 
that has fewer than 500 employees, including em-
ployees of affiliates, and does not have a drug prod-
uct that has been approved under a human drug ap-
plication (as defined in section 735) or a biosimilar 
biological product application (as defined in section 
744G(4)) and introduced or delivered for introduc-
tion into interstate commerce. 
‘‘(d) EFFECT OF FAILURE TO PAY FEES.—A bio-
similar biological product application or supplement sub-
mitted by a person subject to fees under subsection (a) 
shall be considered incomplete and shall not be accepted 
for filing by the Secretary until all fees owed by such per-
son have been paid. 
‘‘(e) CREDITING AND AVAILABILITY OF FEES.— 
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
fees authorized under subsection (a) shall be col-
lected and available for obligation only to the extent 
and in the amount provided in advance in appropria-
tions Acts. Such fees are authorized to remain avail-
able until expended. Such sums as may be necessary 
may be transferred from the Food and Drug Admin-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00114
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
115 
istration salaries and expenses appropriation account 
without fiscal year limitation to such appropriation 
account for salaries and expenses with such fiscal 
year limitation. The sums transferred shall be avail-
able solely for the process for the review of bio-
similar biological product applications. 
‘‘(2) 
COLLECTIONS
AND
APPROPRIATION 
ACTS.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graphs (C) and (D), the fees authorized by this 
section shall be collected and available in each 
fiscal year in an amount not to exceed the 
amount specified in appropriation Acts, or oth-
erwise made available for obligation for such 
fiscal year. 
‘‘(B) USE
OF
FEES
AND
LIMITATION.— 
The fees authorized by this section shall be 
available for a fiscal year beginning after fiscal 
year 2012 to defray the costs of the process for 
the review of biosimilar biological product appli-
cations (including such costs for an additional 
number of full-time equivalent positions in the 
Department of Health and Human Services to 
be engaged in such process), only if the Sec-
retary allocates for such purpose an amount for 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00115
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
116 
such fiscal year (excluding amounts from fees 
collected under this section) no less than 
$20,000,000, multiplied by the adjustment fac-
tor applicable to the fiscal year involved. 
‘‘(C) FEE
COLLECTION
DURING
FIRST 
PROGRAM YEAR.—Until the date of enactment 
of an Act making appropriations through Sep-
tember 30, 2013, for the salaries and expenses 
account of the Food and Drug Administration, 
fees authorized by this section for fiscal year 
2013 may be collected and shall be credited to 
such account and remain available until ex-
pended. 
‘‘(D) PROVISION FOR EARLY PAYMENTS IN 
SUBSEQUENT YEARS.—Payment of fees author-
ized under this section for a fiscal year (after 
fiscal year 2013), prior to the due date for such 
fees, may be accepted by the Secretary in ac-
cordance with authority provided in advance in 
a prior year appropriations Act. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of fiscal years 2013 through 2017, there 
is authorized to be appropriated for fees under this 
section an amount equivalent to the total amount of 
fees assessed for such fiscal year under this section. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00116
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
117 
‘‘(f) COLLECTION OF UNPAID FEES.—In any case 
where the Secretary does not receive payment of a fee as-
sessed under subsection (a) within 30 days after it is due, 
such fee shall be treated as a claim of the United States 
Government subject to subchapter II of chapter 37 of title 
31, United States Code. 
‘‘(g) WRITTEN REQUESTS FOR WAIVERS AND RE-
FUNDS.—To qualify for consideration for a waiver under 
subsection (c), or for a refund of any fee collected in ac-
cordance with subsection (a)(2)(A), a person shall submit 
to the Secretary a written request for such waiver or re-
fund not later than 180 days after such fee is due. 
‘‘(h) CONSTRUCTION.—This section may not be con-
strued to require that the number of full-time equivalent 
positions in the Department of Health and Human Serv-
ices, for officers, employers, and advisory committees not 
engaged in the process of the review of biosimilar biologi-
cal product applications, be reduced to offset the number 
of officers, employees, and advisory committees so en-
gaged.’’. 
SEC. 403. REAUTHORIZATION; REPORTING REQUIREMENTS. 
Part 8 of subchapter C of chapter VII, as added by 
section 402 of this Act, is further amended by inserting 
after section 744H the following: 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00117
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
118 
‘‘SEC. 
744I. 
REAUTHORIZATION; 
REPORTING 
REQUIRE-
MENTS. 
‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 
year 2013, not later than 120 days after the end of each 
fiscal year for which fees are collected under this part, 
the Secretary shall prepare and submit to the Committee 
on Energy and Commerce of the House of Representatives 
and the Committee on Health, Education, Labor, and 
Pensions of the Senate a report concerning the progress 
of the Food and Drug Administration in achieving the 
goals identified in the letters described in section 401(b) 
of the Biosimilar User Fee Act of 2012 during such fiscal 
year and the future plans of the Food and Drug Adminis-
tration for meeting such goals. The report for a fiscal year 
shall include information on all previous cohorts for which 
the Secretary has not given a complete response on all 
biosimilar biological product applications and supplements 
in the cohort. 
‘‘(b) FISCAL REPORT.—Not later than 120 days after 
the end of fiscal year 2013 and each subsequent fiscal year 
for which fees are collected under this part, the Secretary 
shall prepare and submit to the Committee on Energy and 
Commerce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions of the 
Senate a report on the implementation of the authority 
for such fees during such fiscal year and the use, by the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00118
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
119 
Food and Drug Administration, of the fees collected for 
such fiscal year. 
‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 
make the reports required under subsections (a) and (b) 
available to the public on the Internet Web site of the 
Food and Drug Administration. 
‘‘(d) STUDY.— 
‘‘(1) IN GENERAL.—The Secretary shall con-
tract with an independent accounting or consulting 
firm to study the workload volume and full costs as-
sociated with the process for the review of biosimilar 
biological product applications. 
‘‘(2) INTERIM RESULTS.—Not later than June 
1, 2015, the Secretary shall publish, for public com-
ment, interim results of the study described under 
paragraph (1). 
‘‘(3) FINAL
RESULTS.—Not later than Sep-
tember 30, 2016, the Secretary shall publish, for 
public comment, the final results of the study de-
scribed under paragraph (1). 
‘‘(e) REAUTHORIZATION.— 
‘‘(1) 
CONSULTATION.—In 
developing 
rec-
ommendations to present to the Congress with re-
spect to the goals described in subsection (a), and 
plans for meeting the goals, for the process for the 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00119
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
120 
review of biosimilar biological product applications 
for the first 5 fiscal years after fiscal year 2017, and 
for the reauthorization of this part for such fiscal 
years, the Secretary shall consult with— 
‘‘(A) the Committee on Energy and Com-
merce of the House of Representatives; 
‘‘(B) the Committee on Health, Education, 
Labor, and Pensions of the Senate; 
‘‘(C) scientific and academic experts; 
‘‘(D) health care professionals; 
‘‘(E) representatives of patient and con-
sumer advocacy groups; and 
‘‘(F) the regulated industry. 
‘‘(2) 
PUBLIC
REVIEW
OF
RECOMMENDA-
TIONS.—After negotiations with the regulated indus-
try, the Secretary shall— 
‘‘(A) present the recommendations devel-
oped under paragraph (1) to the congressional 
committees specified in such paragraph; 
‘‘(B) publish such recommendations in the 
Federal Register; 
‘‘(C) provide for a period of 30 days for 
the public to provide written comments on such 
recommendations; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00120
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
121 
‘‘(D) hold a meeting at which the public 
may present its views on such recommenda-
tions; and 
‘‘(E) after consideration of such public 
views and comments, revise such recommenda-
tions as necessary. 
‘‘(3) TRANSMITTAL OF RECOMMENDATIONS.— 
Not later than January 15, 2017, the Secretary 
shall transmit to the Congress the revised rec-
ommendations under paragraph (2), a summary of 
the views and comments received under such para-
graph, and any changes made to the recommenda-
tions in response to such views and comments.’’. 
SEC. 404. SUNSET DATES. 
(a) AUTHORIZATION.—Sections 744G and 744H, as 
added by section 402 of this Act, are repealed October 
1, 2017. 
(b) REPORTING REQUIREMENTS.—Section 744I, as 
added by section 403 of this Act, is repealed January 31, 
2018. 
SEC. 405. EFFECTIVE DATE. 
(a) IN GENERAL.—Except as provided under sub-
section (b), the amendments made by this title shall take 
effect on the later of— 
(1) October 1, 2012; or 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00121
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
122 
(2) the date of the enactment of this title. 
(b) EXCEPTION.—Fees under part 8 of subchapter 
C of chapter VII of the Federal Food, Drug, and Cosmetic 
Act, as added by this title, shall be assessed for all bio-
similar biological product applications received on or after 
October 1, 2012, regardless of the date of the enactment 
of this title. 
SEC. 406. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 2 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act, as in effect on the day before 
the date of the enactment of this title, shall continue to 
be in effect with respect to human drug applications and 
supplements (as defined in such part as of such day) that 
were accepted by the Food and Drug Administration for 
filing on or after October 1, 2007, but before October 1, 
2012, with respect to assessing and collecting any fee re-
quired by such part for a fiscal year prior to fiscal year 
2013. 
SEC. 407. CONFORMING AMENDMENT. 
Section 735(1)(B) (21 U.S.C. 379g(1)(B)) is amend-
ed by striking ‘‘or (k)’’. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00122
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
123 
TITLE V—REAUTHORIZATION OF 
BEST 
PHARMACEUTICALS 
FOR CHILDREN ACT AND PE-
DIATRIC RESEARCH EQUITY 
ACT 
SEC. 501. PERMANENT EXTENSION OF BEST PHARMA-
CEUTICALS FOR CHILDREN ACT AND PEDI-
ATRIC RESEARCH EQUITY ACT. 
(a) PROGRAM FOR PEDIATRIC STUDIES OF DRUGS.— 
Section 409I(c) of the Public Health Service Act (42 
U.S.C. 284m(c)) is amended— 
(1) in subsection (c)(1)— 
(A) in the matter preceding subparagraph 
(A), by inserting ‘‘or section 351(m) of this 
Act,’’ after ‘‘Cosmetic Act,’’; 
(B) in subparagraph (A)(i), by inserting 
‘‘or section 351(k) of this Act’’ after ‘‘Cosmetic 
Act’’; and 
(C) by amending subparagraph (B) to read 
as follows: 
‘‘(B)(i) there remains no patent listed pur-
suant to section 505(b)(1) of the Federal Food, 
Drug, and Cosmetic Act; and 
‘‘(ii) every three-year and five-year period 
referred 
to 
in 
subsection 
(c)(3)(E)(ii), 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00123
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
124 
(c)(3)(E)(iii), 
(c)(3)(E(iv), 
(j)(5)(F)(ii), 
(j)(5)(F)(iii), or (j)(5)(F)(iv) of section 505 of 
the Federal Food, Drug and Cosmetic Act, or 
applicable twelve-year period referred to in sec-
tion 351(k)(7) of this Act, and any seven-year 
period referred to in section 527 of the Federal 
Food, Drug, and Cosmetic Act, has ended for 
at least one form of the drug; and’’; 
(2) in subsection (c)(2)— 
(A) in the heading of paragraph (2), by 
striking ‘‘FOR DRUGS LACKING EXCLUSIVITY’’; 
(B) by striking ‘‘under section 505 of the 
Federal Food, Drug, and Cosmetic Act’’; and 
(C) by striking ‘‘505A of such Act’’ and 
inserting ‘‘505A of the Federal Food, Drug, 
and Cosmetic Act or section 351(m) of this 
Act’’; and 
(3) in subsection (e)(1), by striking ‘‘to carry 
out this section’’ and all that follows through the 
end of paragraph (1) and inserting ‘‘$25,000,000 
for each of fiscal years 2013 through 2017.’’. 
(b) PEDIATRIC STUDIES OF DRUGS IN FFDCA.— 
Section 505A (21 U.S.C. 355a) is amended— 
(1) in subsection (d)(1)(A), by adding at the 
end the following: ‘‘If a request under this subpara-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00124
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
125 
graph does not request studies in neonates, such re-
quest shall include a statement describing the ra-
tionale for not requesting studies in neonates.’’; 
(2) by amending subsection (h) to read as fol-
lows: 
‘‘(h) RELATIONSHIP TO PEDIATRIC RESEARCH RE-
QUIREMENTS.—Exclusivity under this section shall only be 
granted for the completion of a study or studies that are 
the subject of a written request and for which reports are 
submitted and accepted in accordance with subsection 
(d)(3). Written requests under this section may consist of 
a study or studies required under section 505B.’’; 
(3) in subsection (k)(2), by striking ‘‘subsection 
(f)(3)(F)’’ and inserting ‘‘subsection (f)(6)(F)’’; 
(4) in subsection (l)— 
(A) in paragraph (1)— 
(i) in the paragraph heading, by strik-
ing ‘‘YEAR ONE’’ and inserting ‘‘FIRST 18- 
MONTH PERIOD’’; and 
(ii) by striking ‘‘one-year’’ and insert-
ing ‘‘18-month’’; 
(B) in paragraph (2)— 
(i) in the paragraph heading, by strik-
ing ‘‘YEARS’’ and inserting ‘‘PERIODS’’; 
and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00125
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
126 
(ii) by striking ‘‘one-year period’’ and 
inserting ‘‘18-month period’’; 
(C) by redesignating paragraph (3) as 
paragraph (4); and 
(D) by inserting after paragraph (2) the 
following: 
‘‘(3) PRESERVATION OF AUTHORITY.—Nothing 
in this subsection shall prohibit the Office of Pedi-
atric Therapeutics from providing for the review of 
adverse event reports by the Pediatric Advisory 
Committee prior to the 18-month period referred to 
in paragraph (1), if such review is necessary to en-
sure safe use of a drug in a pediatric population.’’; 
(5) in subsection (n)— 
(A) in the subsection heading, by striking 
‘‘COMPLETED’’ and inserting ‘‘SUBMITTED’’; 
and 
(B) in paragraph (1)— 
(i) in the text preceding subparagraph 
(A), by striking ‘‘have not been completed’’ 
and inserting ‘‘have not been submitted by 
the date specified in the written request 
issued and agreed upon’’; and 
(ii) by revising subparagraphs (A) and 
(B) to read as follows: 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00126
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
127 
‘‘(A) For a drug for which there remains 
any listed patent or exclusivity protection eligi-
ble for extension under subsection (b)(1) or 
(c)(1) of this section, or any exclusivity protec-
tion eligible for extension under subsection 
(m)(2) or (m)(3) of section 351 of the Public 
Health Service Act, the Secretary shall make a 
determination regarding whether an assessment 
shall be required to be submitted under section 
505B(b). 
‘‘(B) For a drug that has no remaining 
listed patents or exclusivity protection eligible 
for extension under subsection (b)(1) or (c)(1) 
of this section, or any exclusivity protection eli-
gible for extension under subsection (m)(2) or 
(m)(3) of section 351 of the Public Health 
Service Act, the Secretary shall refer the drug 
for inclusion on the list established under sec-
tion 409I of the Public Health Service Act for 
the conduct of studies.’’; 
(6) in subsection (o)(2), by amending subpara-
graph (B) to read as follows: 
‘‘(B) a statement of any appropriate pedi-
atric contraindications, warnings, precautions, 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00127
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
128 
or other information that the Secretary con-
siders necessary to assure safe use.’’; and 
(7) by striking subsection (q) (relating to a sun-
set). 
(c) RESEARCH INTO PEDIATRIC USES FOR DRUGS 
AND BIOLOGICAL PROJECTS IN FFDCA.—Section 505B 
(21 U.S.C. 355c) is amended— 
(1) in subsection (a)— 
(A) in paragraph (1), in the matter before 
subparagraph (A), by inserting ‘‘for a drug’’ 
after ‘‘(or supplement to an application)’’; 
(B) in paragraph (3)— 
(i) by redesignating subparagraph (B) 
as subparagraph (D); and 
(ii) by inserting after subparagraph 
(A) the following: 
‘‘(B) DEFERRAL EXTENSION.—On the ini-
tiative of the Secretary or at the request of the 
applicant, the Secretary may grant an extension 
of a deferral under subparagraph (A) if— 
‘‘(i) the Secretary finds that the cri-
teria specified in subclause (II) or (III) of 
subparagraph (A)(i) continue to be met; 
and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00128
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
129 
‘‘(ii) the applicant submits the mate-
rials required under subparagraph (A)(ii). 
‘‘(C) CONSIDERATION DURING DEFERRAL 
PERIOD.—If the Secretary has under this para-
graph deferred the date by which an assessment 
must be submitted, then until the date specified 
in the deferral under subparagraph (A) (includ-
ing any extension of such date under subpara-
graph (B))— 
‘‘(i) the assessment shall not be con-
sidered late or delayed; 
‘‘(ii) the Secretary shall not classify 
the assessment as late or delayed in any 
report, database, or public posting.’’; and 
(iii) in subparagraph (D), as redesig-
nated, by amending clause (ii) to read as 
follows: 
‘‘(ii) 
PUBLIC
AVAILABILITY.—Not 
later than 60 days after the submission to 
the Secretary of the information submitted 
through the annual review under clause (i), 
the Secretary shall make available to the 
public in an easily accessible manner, in-
cluding through the Web site of the Food 
and Drug Administration— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00129
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
130 
‘‘(I) such information; 
‘‘(II) the name of the applicant 
for the product subject to the assess-
ment; 
‘‘(III) the date on which the 
product was approved; and 
‘‘(IV) the date of each deferral or 
deferral extension under this para-
graph for the product.’’; and 
(C) in paragraph (4)(C)— 
(i) in the first sentence, by inserting 
‘‘partial’’ before ‘‘waiver is granted’’; and 
(ii) in the second sentence, by striking 
‘‘either a full or partial waiver’’ and insert-
ing ‘‘a partial waiver’’; 
(2) in subsection (b)(1), by striking ‘‘After pro-
viding notice in the form of a letter (that, for a drug 
approved under section 505, references a declined 
written request under section 505A for a labeled in-
dication which written request is not referred under 
section 505A(n)(1)(A) to the Foundation of the Na-
tional Institutes of Health for the pediatric studies), 
the Secretary’’ and inserting ‘‘The Secretary’’; 
(3) by amending subsection (d) to read as fol-
lows: 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00130
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
131 
‘‘(d) FAILURE TO MEET REQUIREMENTS.—If a per-
son fails to submit a required assessment described in sub-
section (a)(2), fails to meet the applicable requirements 
in subsection (a)(3), or fails to submit a request for ap-
proval of a pediatric formulation described in subsection 
(a) or (b), in accordance with applicable provisions of sub-
sections (a) and (b)— 
‘‘(1)(A) the Secretary shall issue a letter to 
such person informing such person of such failure; 
‘‘(B) not later than 30 calendar days after the 
issuance of a letter under subparagraph (A), the 
person who receives such letter shall submit to the 
Secretary a written response to such letter; and 
‘‘(C) not later than 45 calendar days after the 
issuance of a letter under subparagraph (A), the 
Secretary shall make such letter, and any response 
to such letter under subparagraph (B), available to 
the public on the Web site of the Food and Drug 
Administration, with appropriate redactions made to 
protect trade secrets and confidential commercial in-
formation, except that, if the Secretary determines 
that the letter under subparagraph (A) was issued 
in error, the requirements of this subparagraph shall 
not apply with respect to such letter; and 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00131
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
132 
‘‘(2)(A) the drug or biological product that is 
the subject of the required assessment, applicable re-
quirements in subsection (a)(3), or required request 
for approval of a pediatric formulation may be con-
sidered misbranded solely because of that failure and 
subject to relevant enforcement action (except that 
the drug or biological product shall not be subject to 
action under section 303); but 
‘‘(B) the failure to submit the required assess-
ment, meet the applicable requirements in subsection 
(a)(3), or submit the required request for approval 
of a pediatric formulation shall not be the basis for 
a proceeding— 
‘‘(i) to withdraw approval for a drug under 
section 505(e); or 
‘‘(ii) to revoke the license for a biological 
product under section 351 of the Public Health 
Service Act.’’; 
(4) by amending subsection (e) to read as fol-
lows: 
‘‘(e) INITIAL PEDIATRIC PLAN.— 
‘‘(1) IN GENERAL.— 
‘‘(A) SUBMISSION.—An applicant who is 
required to submit an assessment under sub-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00132
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
133 
section (a)(1) shall submit an initial pediatric 
plan. 
‘‘(B) TIMING.—An applicant shall submit 
the initial pediatric plan under paragraph (1)— 
‘‘(i) before the date on which the ap-
plicant submits the assessments under sub-
section (a)(2); and 
‘‘(ii) not later than— 
‘‘(I) 60 calendar days after the 
date of end-of-Phase 2 meeting (as 
such term is used in section 312.47 of 
title 21, Code of Federal Regulations, 
or successor regulations); or 
‘‘(II) such other time as may be 
agreed upon between the Secretary 
and the applicant. 
Nothing in this section shall preclude the Sec-
retary from accepting the submission of an ini-
tial pediatric plan earlier than the date other-
wise applicable under this subparagraph. 
‘‘(C) CONTENTS.—The initial pediatric 
plan shall include— 
‘‘(i) an outline of the pediatric studies 
that the applicant plans to conduct; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00133
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
134 
‘‘(ii) any request for a deferral, partial 
waiver, or waiver under this section, along 
with supporting information; and 
‘‘(iii) other information the Secretary 
determines necessary, including any infor-
mation specified in regulations under para-
graph (5). 
‘‘(2) MEETING.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (B), not later than 90 calendar days 
after receiving an initial pediatric plan under 
paragraph (1), the Secretary shall meet with 
the applicant to discuss the plan. 
‘‘(B) WRITTEN
RESPONSE.—If the Sec-
retary determines that a written response to the 
initial pediatric plan is sufficient to commu-
nicate comments on the initial pediatric plan, 
and that no meeting is necessary the Secretary 
shall, not later than 90 days after receiving an 
initial pediatric plan under paragraph (1)— 
‘‘(i) notify the applicant of such deter-
mination; and 
‘‘(ii) provide to the applicant the Sec-
retary’s written comments on the plan. 
‘‘(3) AGREED PEDIATRIC PLAN.— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00134
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
135 
‘‘(A) SUBMISSION.—The applicant shall 
submit to the Secretary a document reflecting 
the agreement between the Secretary and the 
applicant on the initial pediatric plan (referred 
to in this subsection as an ‘agreed pediatric 
plan’). 
‘‘(B) CONFIRMATION.—Not later than 30 
days after receiving the agreed pediatric plan 
under subparagraph (A), the Secretary shall 
provide written confirmation to the applicant 
that such plan reflects the agreement of the 
Secretary. 
‘‘(C) DEFERRAL
AND
WAIVER.—If the 
agreed pediatric plan contains a request from 
the applicant for a deferral, partial waiver, or 
waiver under this section, the written confirma-
tion under subparagraph (B) shall include a 
recommendation from the Secretary as to 
whether such request meets the standards 
under paragraphs (3) or (4) of subsection (a). 
‘‘(D) AMENDMENTS
TO
THE
PLAN.—At 
the initiative of the Secretary or the applicant, 
the agreed pediatric plan may be amended at 
any time. The requirements of paragraph (2) 
shall apply to any such proposed amendment in 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00135
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
136 
the same manner and to the same extent as 
such requirements apply to an initial pediatric 
plan under paragraph (1). The requirements of 
subparagraphs (A) through (C) of this para-
graph shall apply to any agreement resulting 
from such proposed amendment in the same 
manner and to the same extent as such require-
ments apply to an agreed pediatric plan. 
‘‘(4) INTERNAL
COMMITTEE.—The Secretary 
shall consult the internal committee under section 
505C on the review of the initial pediatric plan, 
agreed pediatric plan, and any amendments to such 
plans. 
‘‘(5) MANDATORY
RULEMAKING.—Not later 
than one year after the date of enactment of the 
Food and Drug Administration Reform Act of 2012, 
the Secretary shall promulgate proposed regulations 
and guidance to implement the provisions of this 
subsection. 
‘‘(6) EFFECTIVE DATE.—The provisions of this 
subsection shall take effect 180 calendar days after 
the date of enactment of the Food and Drug Admin-
istration Reform Act of 2012, irrespective of wheth-
er the Secretary has promulgated final regulations 
to carry out this subsection by such date.’’; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00136
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
137 
(5) in subsection (f)— 
(A) in the subsection heading, by inserting 
‘‘DEFERRAL
EXTENSIONS,’’ after ‘‘DEFER-
RALS,’’; 
(B) in paragraph (4)— 
(i) in the paragraph heading, by in-
serting ‘‘DEFERRAL
EXTENSIONS,’’ after 
‘‘DEFERRALS,’’; and 
(ii) in the second sentence, by insert-
ing ‘‘, deferral extensions,’’ after ‘‘defer-
rals’’; and 
(C) in paragraph (6)(D)— 
(i) by inserting ‘‘and deferral exten-
sions’’ before ‘‘requested and granted’’; 
and 
(ii) by inserting ‘‘and deferral exten-
sions’’ after ‘‘the reasons for such defer-
rals’’; 
(6) in subsection (g)— 
(A) in paragraph (1)(A), by striking ‘‘after 
the date of the submission of the application or 
supplement’’ and inserting ‘‘after the date of 
the submission of an application or supplement 
that receives a priority review or 330 days after 
the date of the submission of an application or 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00137
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
138 
supplement that receives a standard review’’; 
and 
(B) in paragraph (2), by striking ‘‘the 
label of such product’’ and inserting ‘‘the label-
ing of such product’’; 
(7) in subsection (h)(1)— 
(A) by inserting ‘‘an application (or sup-
plement to an application) that contains’’ after 
‘‘date of submission of’’; and 
(B) by inserting ‘‘if the application (or 
supplement) receives a priority review, or not 
later than 330 days after the date of submis-
sion of an application (or supplement to an ap-
plication) that contains a pediatric assessment 
under this section, if the application (or supple-
ment) receives a standard review,’’ after ‘‘under 
this section,’’; 
(8) in subsection (i)— 
(A) in paragraph (1)— 
(i) in the paragraph heading, by strik-
ing ‘‘YEAR ONE’’ and inserting ‘‘FIRST 18- 
MONTH PERIOD’’; and 
(ii) by striking ‘‘one-year’’ and insert-
ing ‘‘18-month’’; 
(B) in paragraph (2)— 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00138
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
139 
(i) in the paragraph heading, by strik-
ing ‘‘YEARS’’ and inserting ‘‘PERIODS’’; 
and 
(ii) by striking ‘‘one-year period’’ and 
inserting ‘‘18-month period’’; 
(C) by redesignating paragraph (3) as 
paragraph (4); and 
(D) by inserting after paragraph (2) the 
following: 
‘‘(3) PRESERVATION OF AUTHORITY.—Nothing 
in this subsection shall prohibit the Office of Pedi-
atric Therapeutics from providing for the review of 
adverse event reports by the Pediatric Advisory 
Committee prior to the 18-month period referred to 
in paragraph (1), if such review is necessary to en-
sure safe use of a drug in a pediatric population.’’; 
(9) by striking subsection (m) (relating to inte-
gration with other pediatric studies); and 
(10) by redesignating subsection (n) as sub-
section (m). 
(d) PEDIATRIC STUDIES OF BIOLOGICAL PRODUCTS 
IN PHSA.—Section 351(m)(1) of the Public Health Serv-
ice Act (42 U.S.C. 262(m)(1)) is amended by striking ‘‘(f), 
(i), (j), (k), (l), (p), and (q)’’ and inserting ‘‘(f), (h), (i), 
(j), (k), (l), (n), and (p)’’. 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00139
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
140 
(e) APPLICATION; TRANSITION RULE.— 
(1) APPLICATION.—Notwithstanding any provi-
sion of section 505A and 505B of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355a, 355c) 
stating that a provision applies beginning on the 
date of the enactment of the Best Pharmaceuticals 
for Children Act of 2007 or the date of the enact-
ment of the Pediatric Research Equity Act of 2007, 
any amendment made by this Act to such a provi-
sion applies beginning on the date of the enactment 
of this Act. 
(2) TRANSITIONAL RULE FOR ADVERSE EVENT 
REPORTING.—With respect to a drug for which a la-
beling change described under section 505A(l)(1) or 
505B(i)(1) of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 355a(l)(1); 355c(i)(1)) is approved 
or made, respectively, during the one-year period 
that ends on the day before the date of enactment 
of this Act, the Secretary shall apply section 505A(l) 
and section 505B(i), as applicable, to such drug, as 
such sections were in effect on such day. 
(f) 
CONFORMING
AMENDMENT.—Section 
499(c)(1)(C) of the Public Health Service Act (42 U.S.C. 
290b(c)(1)(C)) is amended by striking ‘‘for which the Sec-
retary issues a certification in the affirmative under sec-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00140
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
141 
tion 505A(n)(1)(A) of the Federal Food, Drug, and Cos-
metic Act’’. 
(g) PUBLIC MEETING ON PEDIATRIC CANCERS.— 
Not later than December 31, 2013, the Secretary of 
Health and Human Services shall hold a public meeting 
on the impact of sections 505A and 505B of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355c) 
on the development of new therapies for children with can-
cer. 
SEC. 502. FOOD AND DRUG ADMINISTRATION REPORT. 
(a) IN GENERAL.—Not later than four years after 
the date of enactment of this Act and every five years 
thereafter, the Secretary of Health and Human Services 
shall prepare and submit to the Committee on Health, 
Education, Labor and Pensions of the Senate and the 
Committee on Energy and Commerce of the House of 
Representatives, and make publicly available, including 
through posting on the Web site of the Food and Drug 
Administration, a report on the implementation of section 
505A and 505B. 
(b) CONTENTS.—The report described in paragraph 
(1) shall include— 
(1) an assessment of the effectiveness of sec-
tions 505A and 505B in improving information 
about pediatric uses for approved drugs and bio-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00141
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
142 
logics, including the number and type of labeling 
changes made since the date of enactment of this 
Act; 
(2) the number of waivers and partial waivers 
granted under section 505B since the date of enact-
ment of this Act, and the reasons such waivers and 
partial waivers were granted; 
(3) the number of deferrals and deferral exten-
sions granted under section 505B since the date of 
enactment of this Act, and the reasons such defer-
rals and deferral extensions were granted; 
(4) the number of letters issued under section 
505B(d); 
(5) an assessment of the timeliness and effec-
tiveness of pediatric study planning since the date of 
enactment of this Act, including the number of pedi-
atric plans not submitted in accordance with the re-
quirements of section 505B(e) and any resulting 
rulemaking; 
(6) the number of written requests issued, ac-
cepted, and declined under section 505A since the 
date of enactment of this Act, and a listing of any 
important gaps in pediatric information as a result 
of such declined requests; 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00142
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
143 
(7) a description and current status of referrals 
made under section 505A(n); 
(8) an assessment of the effectiveness of study-
ing drugs for rare diseases under 505A; 
(9) an assessment of the effectiveness of study-
ing drugs for children with cancer under 505A and 
505B, and any recommendations for modifications 
to the programs under such sections that would lead 
to new and better therapies for children with cancer; 
(10) an assessment of the effectiveness of 
studying drugs in the neonate population under 
505A and 505B; 
(11) an assessment of the effectiveness of 
studying biological products in pediatric populations 
under 505A and 505B; 
(12) an assessment of the Secretary’s efforts to 
address the suggestions and options described in the 
report required under 505A(p); 
(13) any suggestions for modification to the 
programs that would improve pediatric drug re-
search and increase pediatric labeling of drugs and 
biologics that the Secretary determines to be appro-
priate. 
(c) STAKEHOLDER COMMENT.—At least 180 days 
prior to the submission of the report required in para-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00143
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
144 
graph (1), the Secretary shall consult with representatives 
of patient groups, including pediatric patient groups, con-
sumer groups, regulated industry, academia, and other in-
terested parties to obtain any recommendations or infor-
mation relevant to the study and report including sugges-
tions for modifications that would improve pediatric drug 
research and pediatric labeling of drugs and biologics. 
SEC. 503. INTERNAL COMMITTEE FOR REVIEW OF PEDI-
ATRIC PLANS, ASSESSMENTS, DEFERRALS, 
DEFERRAL EXTENSIONS, AND WAIVERS. 
Section 505C (21 U.S.C. 355d) is amended— 
(1) in the section heading, by inserting ‘‘DE-
FERRAL
EXTENSIONS,’’ after ‘‘DEFERRALS,’’; 
and 
(2) by inserting ‘‘neonatology’’ after ‘‘pediatric 
ethics’’. 
SEC. 504. STAFF OF OFFICE OF PEDIATRIC THERAPEUTICS. 
Section 6(c) of the Best Pharmaceuticals for Children 
Act (21 U.S.C. 393a(c)) is amended— 
(1) in paragraph (1), by striking ‘‘and’’ at the 
end; 
(2) by redesignating paragraph (2) as para-
graph (4); 
(3) by inserting after paragraph (1) the fol-
lowing: 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00144
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
145 
‘‘(2) one or more additional individuals with ex-
pertise in neonatology; 
‘‘(3) one or more additional individuals with ex-
pertise in pediatric epidemiology; and’’. 
SEC. 505. CONTINUATION OF OPERATION OF PEDIATRIC 
ADVISORY COMMITTEE. 
Section 14(d) of the Best Pharmaceuticals for Chil-
dren Act (42 U.S.C. 284m note) is amended by striking 
‘‘during the five-year period beginning on the date of the 
enactment of the Best Pharmaceuticals for Children Act 
of 2007’’ and inserting ‘‘to carry out the advisory commit-
tee’s responsibilities under sections 505A, 505B, and 
520(m) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355a, 355c, and 360j(m))’’. 
SEC. 506. PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC 
DRUGS ADVISORY COMMITTEE. 
Section 15(a) of the Best Pharmaceuticals for Chil-
dren Act (Public Law 107–109), as amended by section 
502(e) of the Food and Drug Administration Amendments 
Act of 2007 (Public Law 110–85), is amended— 
(1) in paragraph (1)(D), by striking ‘‘section 
505B(f)’’ and inserting ‘‘section 505C’’; and 
(2) in paragraph (3), by striking ‘‘during the 
five-year period beginning on the date of the enact-
ment of the Best Pharmaceuticals for Children Act 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00145
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
146 
of 2007’’ and inserting ‘‘to carry out the Sub-
committee’s responsibilities under this section’’. 
TITLE VI—FOOD AND DRUG AD-
MINISTRATION ADMINISTRA-
TIVE REFORMS 
SEC. 601. PUBLIC PARTICIPATION IN ISSUANCE OF FDA 
GUIDANCE DOCUMENTS. 
Section 701(h)(1) (21 U.S.C. 371(h)(1)) is amended 
by striking subparagraph (C) and inserting the following: 
‘‘(C) For any guidance document that sets 
forth initial interpretations of a statute or regu-
lation, sets forth changes in interpretation or 
policy that are of more than a minor nature, in-
cludes complex scientific issues, or covers highly 
controversial issues— 
‘‘(i) the Secretary— 
‘‘(I) at least 30 days before 
issuance of a draft of such guidance 
document, shall publish notice in the 
Federal Register of the Secretary’s in-
tent to prepare such guidance docu-
ment; and 
‘‘(II) during preparation and be-
fore issuance of such guidance docu-
ment, may meet with interested stake-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00146
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
147 
holders, including industry, medical, 
and scientific experts and others, and 
solicit public comment; 
‘‘(ii) if the Secretary for good cause 
finds that, with respect to such guidance 
document, compliance with clause (i) is im-
practicable, unnecessary, or contrary to the 
public interest— 
‘‘(I) the Secretary shall publish 
such finding and a brief statement of 
the reasons for such finding in the 
Federal Register; 
‘‘(II) clause (i) shall not apply 
with respect to such guidance docu-
ment; and 
‘‘(III) during a 90-day period be-
ginning not later than the date of 
issuance of the draft of such guidance 
document, the Secretary may meet 
with interested stakeholders, including 
industry, medical, and scientific ex-
perts and others, and shall solicit pub-
lic comment; 
‘‘(iii) beginning on the date of enact-
ment of the Food and Drug Administra-
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00147
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS
148 
tion Reform Act of 2012, upon issuance of 
a draft guidance document under clause (i) 
or (ii), the Secretary shall— 
‘‘(I) designate the document as 
draft or final; and 
‘‘(II) not later than 18 months 
after the close of the comment period 
for such guidance, issue a final 
version of such guidance document in 
accordance with clauses (i) and (ii); 
‘‘(iv) the Secretary may extend the 
deadline for issuing final guidance under 
clause (iii)(II) by not more than 180 days 
upon submission by the Secretary of a no-
tification of such extension in the Federal 
Register; 
‘‘(v) if the Secretary issues a draft 
guidance document and fails to finalize the 
draft by the deadline determined under 
clause (iii)(II), as extended under clause 
(iv), the Secretary shall, beginning on the 
date of such deadline, treat the draft as 
null and void; and 
‘‘(vi) not less than every 5 years after 
the issuance of a final guidance document 
VerDate Mar 15 2010 
22:01 May 25, 2012
Jkt 019200
PO 00000
Frm 00148
Fmt 6652
Sfmt 6201
E:\BILLS\H5651.RH
H5651
srobinson on DSK4SPTVN1PROD with BILLS